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Summary 	
An epithelial-mesenchymal transition (EMT) is a fundamental example 
of cell plasticity, involving a reversible switch from epithelial to mesenchymal 
cell states. An EMT endows stationary epithelial cells with migratory and 
invasive potential, leads to intravasation into the blood circulation and 
extravasation to the distant organ. To promote metastatic outgrowth, 
mesenchymal cells undergo a reverse process of mesenchymal-epithelial 
transition (MET). Therefore, it is important to understand the underlying 
mechanisms of epithelial-mesenchymal plasticity to design effective 
therapeutic approaches that revert EMT and prevent tumor cell invasion and 
metastasis. 
The dynamic cell state transitions during EMT imply a role for 
chromatin rearrangements that are established by epigenetic regulators. 
However, we still do not fully understand the differences between the 
epigenetically regulated mechanisms defining the transient cell state 
transitions of a reversible EMT and the fixed cell status of an irreversible EMT. 
To delineate these differences, we have generated from murine mammary 
epithelial cancer cells a novel in vitro irreversible EMT model as compared to 
a reversible EMT model. Reversible EMT is induced by TGF-β, a potent 
inducer of EMT. Upon removal of TGF-β, mesenchymal cells undergo a MET 
and revert to the epithelial state. In contrast, in vitro irreversible EMT cells 
maintain their mesenchymal state even after removal of the EMT-inducing 
growth medium. These EMT systems have provided us a unique opportunity 
to identify the de novo established epigenetic modifiers which maintain the 
mesenchymal state. 
Gene expression analysis has revealed a remarkable difference 
between the reversible and the irreversible EMT systems. Interestingly, 
irreversible EMT cells exhibit a highly aggressive phenotype in terms of tumor 
growth rate and metastasis formation as compared to the reversible EMT 
cells. To identify the epigenetic regulators contributing to the maintenance of 
the mesenchymal cell state and the aggressive phenotype of irreversible EMT 
cells, we have used several pharmacological inhibitors targeting various 
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epigenetic modifiers. We have found that histone deacetylase (HDAC) 
inhibitors partially revert irreversible EMT cells into an epithelial cell state. Due 
to the merely partial contribution of HDACs to an irreversible EMT, we have 
further explored additional contributors to the maintenance of the 
mesenchymal cell state. HDACs are involved in several corepressor 
complexes to exert their specific functions. The Mbd3/NuRD complex is one 
of the corepressor complexes containing HDAC1/2. It plays an important role 
in the generation of induced pluripotent stem (iPS) cells from mouse 
embryonic fibroblasts (MEFs), indicating a key role in cellular plasticity. 
Notably, Mbd3 is the only methyl binding domain protein which is not able to 
bind to the methylated cytosines due to an amino acid substitution in the 
methyl binding domain. Instead, it is thought that it recognizes the DNA 
demethylation intermediate 5-hydroxymethyl cytosine which is generated by 
Tet hydroxylases. 
Using loss of function experiments, we demonstrate that the 
Mbd3/NuRD complex, involving histone deacetylases (HDACs) and Tet2 
hydroxylase, acts as an epigenetic block in epithelial-mesenchymal plasticity. 
Interestingly, these epigenetic factors keep the mesenchymal cells in a stable 
state and promote the aggressive cancer cell phenotype by regulating a wide-
range of gene networks. The pharmacological inhibition of HDACs and 
ablation of Mbd3 and/or Tet2 leads to a MET as well as to diminished tumor 
growth and metastasis formation. These results provide important insights into 
the epigenetic regulation of epithelial-mesenchymal plasticity and identify 
novel therapeutic targets to interfere with primary tumor growth and 
metastasis formation. In particular, the development of specific inhibitors of 
Tet hydroxylases and their combinatorial use with HDAC inhibitors may be an 
effective therapeutic approach to prevent tumor progression and metastasis. 
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1 Introduction 	
1.1 Epithelial to mesenchymal transition 
Epithelium is the one of the most common and abundant type of tissue. It is 
found really early in the embryonic development and forms the lining of most 
tissues. Epithelial cells are converted to mesenchymal cells through 
“epithelial-mesenchymal transformation”. Elizabeth Hay first observed this 
process during the primitive streak formation in the chick embryos, with 
dramatic morphological changes of the epithelial cells (Hay, 1995).  However, 
after the discovery of reverse mechanism of mesenchymal to epithelial 
transition, the term “transformation” was replaced by “transition”, thereby 
reflecting the reversibility of the process (Thiery, 2002). (Wicki et al., 2006) 
1.1.1 Basics of EMT 
The epithelium is a highly organized tissue consisting of single layered 
squamous or single/multilayered sheets of cuboidal and columnar cells. 
Simple epithelium is formed by epithelial cells characterized by apical-basal 
polarity, cell-cell junctions and their attachment to the basal lamina. These 
structures maintain the tissue integrity and stabilize the epithelial cells within a 
restricted area (Baum et al., 2008). Upon induction of EMT, epithelial cells 
undergo morphological and functional changes by disruption of the cell 
junctions and apical-basal polarity, and reorganizing their actin cytoskeleton 
that gives rise to motile cells which invades the basement membrane (Thiery 
et al., 2009). The hallmarks of EMT are discussed below (Figure 1). 
i) Disruption of cell-cell junctions during EMT: The polarized epithelial 
cells are tightly connected through specialized intercellular junctions such as 
tight junctions, adherens junctions, desmosomes and gap junctions (Thiery 
and Sleeman, 2006). Tight junctions provide a physical intercellular barrier 
and prevent the fluid exchange between the luminal and stromal 
compartments. They reside at the boundary between the apical and lateral 
surface. Claudins and zona occludens (ZO-1, ZO-2 and ZO-3) are the most 
important components of the tight junctions (Giepmans and van Ijzendoorn, 
2009). Upon induction of EMT, claudins/zona occludens are downregulated 
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and ZO-1 translocates to the cytoplasm (Huang et al., 2012). Adherens 
junctions reside at the lateral surface and mediate the cell-cell contact along 
with tight junctions. E-cadherin is a calcium-dependent, single-span 
transmembrane glycoprotein, which belongs to the classical cadherins family 
(Yilmaz and Christofori, 2009). E-cadherin binds to β-catenin through its 
cytoplasmic domain and β-catenin binds to α-catenin, which mediates the 
interaction with actin microfilaments (Huang et al., 2012). EMT induces loss of 
E-cadherin and gain of N-cadherin, known as cadherin switch involved during 
development and tumor cell invasion (Cavallaro et al., 2002; Christofori, 
2003). Desmosomes, adhesive junction components interacting with the 
intermediate cytokeratin filaments are disrupted during EMT (Huang et al., 
2012). Gap junctions mediate the exchange of ions and small molecules 
between the cells through hemi-channels. Reducing connexin levels diminish 
the integrity of gap junctions (Lamouille et al., 2014). 
 
 
 
Figure 1: Hallmarks of EMT. The initial steps of epithelial-mesenchymal transition 
(EMT) are the disassembly of cell–cell contacts, tight junctions, adherens junctions, 
desmosomes and gap junctions and E-cadherin switch to N-cadherin. Apical-basal 
polarity turns into front-rear polarity. The expression of epithelial genes is repressed, 
accompanied by mesenchymal gene activation. Further, cortical actin is reorganized 
into stress fibers, cells secrete matrix metalloproteinases (MMPs) leads to 
remodeling of extracellular matrix (ECM) and drive migration and invasion by the 
formation of cell-matrix adhesions through, integrins. EMT is able to undergo reverse 
process mesenchymal–epithelial transition (MET) and revert to the epithelial state. 
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ii) Loss of apical-basal polarity: The apical-basal polarity of the 
epithelial cells leads to the vectorial transportation of soluble factors and 
cellular components. Upon EMT, the apical-basal polarity turns into front-rear 
polarity to provide directional migration (Nelson, 2009). Epithelial polarity is 
mediated by several group of proteins such as partitioning defective (Par), 
Crumbs, and Scribble, and lipids such as phosphoinositides and Rho 
GTPases (Cdc42, Rac1 and RhoA). The Crumbs complex leads to immature 
apical junction by acting with the Cdc42-Par3-Par6-atypical protein kinase C 
(aPKC) and the Scribble complexes, which matures into tight junctions and 
adherens junctions (Jaffe and Hall, 2005; Rodriguez-Boulan and Macara, 
2014). 
iii) Cytoskeletal rearrangements: Cytoskeleton provides tissue integrity 
and mechanical strength via actin cytoskeleton, microtubules and 
intermediate filaments. Cytoskeleton is rearranged during EMT and act as a 
driving force for cell migration and invasion (Sun et al., 2015). In epithelial 
cells, actin is localized cortically, whereas in mesenchymal cells actin is 
reorganized into stress fibers (Thiery et al., 2009). Actin machinery is mainly 
regulated by Rho GTPase family which conduct signals from chemokines, 
growth factors and adhesion receptors to actin remodeling. RhoA, Rac1, 
Cdc42 belonging to RhoGTPase family are important regulators of cell 
migration and invasion. RhoA is responsible of actin stress fiber formation, 
Rac1 and Cdc42 mediate lamellipodia and filopodia formation, respectively 
(Yilmaz and Christofori, 2009). Microtubules are also regulated during EMT 
induced cell migration. Upon EMT, microtubules that are uniformly distributed 
in cytoplasm translocate mainly to the protrusions and drive cell migration. 
Intermediate filaments are dramatically rearranged during EMT, exhibiting a 
switch between different types of intermediate filaments. For example, 
epithelial cells are rich with type I keratin, while mesenchymal cells are 
enriched with type III vimentin (Sun et al., 2015). 
iv) ECM remodeling: Extracellular matrix (ECM) provides a 3D 
structure to a cell to regulate tissue homeostasis, cell proliferation, 
differentiation and migration. Basal lamina is a specialized type of ECM, which 
segregates epithelium from the surrounding stroma. Epithelial tissue interacts 
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with the basal lamina through integrins (Bonnans et al., 2014; Yilmaz and 
Christofori, 2009). Integrins are transmembrane proteins that are composed 
by α and β chains and different combinations of α/β subunits can form 24 
different integrins in a cell-type or a stage-specific manner (Hynes, 2002), 
though a handful of them are specific to the basal lamina. During EMT, 
epithelial cells lose their contact with the basal lamina. Mesenchymal cells 
remodel the basal lamina by secreting new components of ECM, 
downregulating some epithelial integrins and upregulating/synthesizing new 
integrins (Radisky, 2005; Yilmaz and Christofori, 2009). For example, 
epithelial-specific α6β4 integrin is epigenetically silenced during EMT (Yang et 
al., 2009), while α5β1 integrin is induced in mesenchymal cells which regulates 
the cell adhesion to fibronectin, increased during EMT and promotes cell 
migration (Maschler et al., 2005). Interaction of α1β1 or α2β1 integrins with 
collagen type 1 induces EMT by downregulating E-cadherin and α5β8 integrin 
induces the matrix metallaproteinases (MMPs) expression and 
liberate/activate TGF-β, a potent inducer of EMT (Araya et al., 2006; Yilmaz 
and Christofori, 2009). 
1.1.2 EMT in physiological contexts 
EMT is classified in three different subgroups. Type 1 EMT is 
associated with the developmental EMT, which leads to the formation of 
different tissue types with various functions. Type 2 EMT involved in 
physiological context such as wound healing, tissue remodeling, and 
pathological processes such as organ fibrosis. Type 3 EMT is characterized in 
the pathological context such as cancer with the uncontrolled systemic 
invasion of cancer cells. Although, these three types of EMT share common 
features, they also exhibit distinct characteristics according to the cellular 
context (Figure 2) (Kalluri and Weinberg, 2009; Nieto, 2013). 
Type 1 EMT is involved at different stages of embryonic development, 
including mesoderm formation, neural crest and heart valve development, as 
well as secondary plate formation. The transition between epithelial and 
mesenchymal cells is not necessarily an irreversible commitment. Several 
rounds of EMT and MET are required during organ formation referred to as 
primary, secondary and tertiary EMT events. During gastrulation, epithelial 
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cells of the single layer epiblast undergo primary EMT and migrate from the 
primitive streak to form the mesoderm and endoderm. Later, the  
 
 
 
Figure 2: Different types of EMT. A) Type 1 EMT is associated with developmental 
EMT. During gastrulation, the primitive epithelium, specifically the epiblast, 
undergoes primary EMT and migrates from the primitive streak, giving rise to primary 
mesenchyme. Further lineage specifications are established by MET and with 
several rounds of EMT. B) Type 2 EMT involved in the physiological context such as 
wound healing. C) Type 3 EMT is characterized in the pathological context such as 
cancer. Primary epithelial cancer cells undergo an EMT which endows cells with 
migratory and invasive potential to invade their basement membrane (Adapted from 
(Kalluri and Weinberg, 2009)).  
 
mesenchymal cells revert to a transient epithelial state, which forms the 
notochord, the somites, primordia of the urogenital system, the somatopleure 
and splanchnopleure. Except the notochord, a second round of EMT is 
observed to give rise to more differentiated cell types. For instance, the dorsal 
part of the somites give rise to dermis and muscle satellite cells while the 
ventral somites generate the vertebrae, tendons and ribs. Somatopleure 
generates the connective tissue of body wall muscle, while the 
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Splanchnopleure gives rise to haematopoietic, endocardial progenitors and 
later to the endocardial cushions which are the progenitors of heart valves via 
tertiary EMT. In neural crest formation, neural crest cells undergo EMT and 
gain migratory capacity for long distances and generate the peripheral 
nervous system, some endocrine cells and melanocytes (Thiery et al., 2009; 
Yang and Weinberg, 2008) (Nieto, 2013).  
 Type 2 EMT plays a role during wound healing. Keratinocytes undergo 
an EMT-like process at the border of the wound as a physiological response 
to injury. In addition, EMT is not only involved in the physiological condition, 
but also during pathological organ fibrosis. In fibrosis, epithelial cells undergo 
an EMT and give rise to myofibroblast cells in renal tissue (Iwano et al., 
2002). The same mechanism is also observed in lens epithelium, 
endothelium, hepatocytes and cardiomyocytes during tissue fibrosis. 
Myofibroblasts together with the immune cells deposit excessive amount of 
ECM components such as collagens, laminins, elastins and tenacins which 
leads to organ failure (Kalluri and Weinberg, 2009; Thiery et al., 2009). 
Type 3 EMT accompanies cancer progression in epithelial tumors. 
Upon EMT, stationary epithelial cells lose their cell-cell junctions and acquire 
motility to invade their basement membrane. EMT process induces the 
dissemination of tumor cells and intravasation into the blood circulation and 
extravasation into a distant organ. It is proposed that the reverse process 
MET in the distant tissue is crucial to promote metastatic colonization. EMT is 
also implicated in acquisition of stem-like properties, drug resistance and 
immune surveillance (Thiery et al., 2009). The role of EMT in tumor 
progression and the contribution of EMT/MET plasticity to tumor metastasis 
will be discussed in detail in the next chapters (1.1.3) and (1.1.4), 
respectively. 
1.1.3 EMT in tumor progression and metastasis 
Carcinomas, derived from epithelial tumor cells are the cause of 90% 
mortality in human cancers (Mehlen and Puisieux, 2006). Tumor progression 
and metastasis is proposed as a multistep process of morphological 
aberrations accompanied by genetic and epigenetic alterations. Only a subset 
of cells that have accomplished full malignant transformation can leave the 
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primary tumor site and seed for metastasis. This is referred to as the linear 
progression model and it is based on the observations of the association of 
the primary tumor size with high metastatic incidence.  However, there is also 
another model, termed as the parallel progression model, suggesting the 
neoplastic cells might disseminate long before the detectable tumors due to 
the growth rates of primary tumors (Klein, 2009). 
The metastatic cascade as shown in Figure 3 involves several steps 
from the formation of the primary tumor until the successful colonization of the 
tumor cells at the distant site. Tumor cells exhibit an excessive proliferation 
rate in the epithelial primary tumors and require blood vessels to survive, a 
process called angiogenesis. Subpopulation of stationary epithelial tumor cells 
gains migratory and invasive capacity, migrate through the basement 
membrane into the blood circulation. Only a subset of cells that are able to 
survive in the blood circulation extravasate into the distant organ. It is 
proposed that mesenchymal cells revert back to the epithelial state in the 
distant organ to form the metastatic colonization (Chambers et al., 2002; 
Hanahan and Weinberg, 2011).  
EMT is proposed as a crucial mechanism in different stages of cancer 
progression from benign adenoma to malignant carcinoma. It has been shown 
that EMT endows epithelial tumor cells with migratory and invasive properties 
in vitro and in vivo (Tiwari et al., 2012). Epithelial tumor cell de-differentiation 
is observed at the invasive front with loss of epithelial markers and gain of 
mesenchymal phenotype (Kirchner and Brabletz, 2000). Additionally, loss of 
E-cadherin, a profound marker of EMT correlates with poor patient survival 
rate in many carcinomas (Berx et al., 2007). However, a full EMT 
phenomenon is rarely observed in the clinical samples, thus involvement of 
EMT during tumor cell invasion is still under debate (Christofori, 2006). On the 
contrary, partial EMT, the coexistence of epithelial and mesenchymal markers 
is a more frequently observed event in vivo (Berx et al., 2007). Difficulties to 
observe partial EMT can be circumvented by in vivo lineage tracing 
experiments (Beck and Blanpain, 2013). 
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Figure 3: EMT/MET plasticity in metastatic cascade. (1) Primary epithelial tumor 
cells (green) exhibit high proliferation (2) Epithelial cells undergo either partial or full 
EMT (blue) and gain migratory potential (3) Migratory mesenchymal cells invade 
through the basement membrane (4) intravasate into the blood circulation (5) as 
clusters or single circulating tumor cells (CTCs) with mesenchymal characteristics (6) 
extravasate to the distant organ (7) invade parenchyma, enter a dormant state or 
undergo MET (8) start colonizing (9) form metastatic outgrowth.  
 
Single or clusters of circulating tumor cells (CTCs) from breast cancer 
patients exhibit EMT phenotype (Yu et al., 2013) which is highly correlated 
with the metastatic disease, indicating the involvement of EMT in the 
metastatic outgrowth (Kallergi et al., 2011). However, distant metastases 
mostly exhibit an epithelial phenotype brought the idea of dynamic regulation 
of EMT process. It is proposed that EMT program is activated during invasion, 
dissemination process and upon arrival of tumor cells to the distant site, the 
reverse process MET takes place to form metastatic outgrowth (Thiery, 2002). 
Even though the contribution of EMT/MET plasticity has been demonstrated in 
several studies (Ocaña et al., 2012; Tsai et al., 2012), the role of EMT to 
promote metastatic outgrowth is still hotly debated (Tarin, 2005; Thomson et 
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al., 2005). Epithelial-mesenchymal plasticity will be further discussed in detail 
in the next chapter. 
1.1.4 Plasticity of EMT 
 Plasticity of a cell refers to the reversible changes in phenotypic cell 
states such as EMT. EMT is a fundamental example of cell plasticity that 
involves a reversible switch within a spectrum of fully epithelial and 
mesenchymal cell states by involving partial EMT/MET cell states. Partial 
EMT/MET cell states are often accompanied by a higher degree of cell 
plasticity due to the acquired flexibility for rapid transition between cell states. 
The plastic nature of EMT is a shared mechanism between physiological and 
pathological conditions, such as development and cancer, respectively 
(Figure 4) (Nieto et al., 2016; Tsai and Yang, 2013).  
 
Figure 4: Plasticity of EMT. EMT is a reversible switch within a spectrum of the fully 
epithelial and mesenchymal cell states by involving the intermediate cell states. The 
color transitions represent hypothetical transitions.  
 
 The crucial role of EMT/MET plasticity is observed in early embryonic 
development (Nieto, 2013). (See chapter: EMT in physiological context). The 
best-studied example of MET is during kidney development. During this 
process, excretory tubules undergo MET which is induced by collecting duct 
system invasion through area of mesenchymal cells. The cells start polarizing 
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and establishing cell-cell contacts to form the kidney tubules (Yang and 
Weinberg, 2008). 
 EMT plasticity is also involved in induced pluripotent stem cells (iPSCs) 
generation, a cell-reprogramming process established by the overexpression 
of Oct4 (Pou5f1), Klf4, Sox2, and c-Myc (OKSM) in somatic cells (Apostolou 
and Hochedlinger, 2013). It has been shown that MET is a prerequisite in the 
initiation phase of the reprogramming of MEFs to iPS cells (Fu et al., 2011; 
Samavarchi-Tehrani et al., 2010). MET is observed with the upregulation of 
epithelial markers E-cadherin and Epcam, accompanied by downregulation of 
mesenchymal markers Snail and N-cadherin during cell reprogramming 
(Samavarchi-Tehrani et al., 2010). It has been also suggested that 
overexpression of Snail, and the depletion of E-cadherin suppresses MET 
dramatically impairing the cell reprogramming process (Li et al., 2010). 
Additionally, Klf4, one of the reprogramming factors, which is responsible in 
the maintenance of epithelial phenotype, binds directly to the E-cadherin 
promoter, thereby inducing a MET during iPSC formation (Polo and 
Hochedlinger, 2010). 
 The dynamic transitions from epithelial to mesenchymal cell states 
have been proposed as a crucial mechanism promoting tumor invasion and 
metastatic dissemination (Baum et al., 2008; Thiery, 2002). However, the role 
of EMT/MET plasticity in the formation of secondary tumors at the metastatic 
site is still under debate. As it has been shown in the metastatic squamous 
cell carcinoma model, the “reversible” EMT cells with the Twist1 inactivation at 
the metastatic site has higher metastatic colonization in the lungs compared 
to the “irreversible” EMT cells that constitutively express Twist1. Depletion of 
Twist1 led to a MET with increased proliferation rate. Twist1 activation 
irrespective of the “reversible” or “irreversible” condition led to an increase in 
the number of CTCs and extravasated tumor cells into the lungs, indicating 
the role of EMT during dissemination (Tsai et al., 2012). This study provides in 
vivo evidence to the necessity of MET during metastatic colonization. 
Requirement of MET in the metastatic colonization has been also suggested 
by downregulation of EMT activator transcription factor Prrx1 at the metastatic 
site (Ocaña et al., 2012). Several reports suggested that re-differentiation 
through MET is required for the switch from EMT-associated growth arrest to 
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the higher proliferating epithelial cells to form the metastatic outgrowth 
(Brabletz, 2012). It can be argued that some therapeutic approaches may 
lead to the reversion of EMT that enhances the metastatic outgrowth.  
 It is proposed that mesenchymal state is induced and maintained by 
continuous microenvironmental signals. Removal of those signals brings the 
cells to their default epithelial state (Tam and Weinberg, 2013). For instance, 
upon adding TGF-β, epithelial cells undergo an EMT and with the removal of 
TGF-β, mesenchymal cells revert back to their epithelial state (Waldmeier et 
al., 2012). However, it is important to note that we still do not have enough 
evidence to understand whether MET-driven epithelial cells are identical with 
their initial epithelial counterparts. It is more likely that MET-derived epithelial 
cells are different than their ancestors, which is implicated during 
developmental processes.   
1.1.5 EMT in breast cancer 
 Breast cancer is the most commonly diagnosed cancer in women. 90% 
of the breast cancer mortality is due to the local invasion and metastasis 
(Wang and Zhou, 2011). Breast cancer is heterogeneous disease with 
different subtypes characterized among different individuals as well as within 
the same tumors (Ellsworth et al., 2017). Characterization of the diversity of 
breast cancers is important for better prognosis and to apply appropriate 
therapy (Schnitt, 2010).  
 Initially, breast cancer subtypes were classified according to their 
morphology. Later on, immunopathological differences were also taken into 
account to assess them by estrogen receptor (ER), progesterone receptor 
(PR), and human epidermal receptor 2 (HER2). ER+ tumors are targeted with 
ER antagonists or aromatase inhibitors, which are anti-estrogen therapy 
(Jordan and Brodie, 2007). PR status does not add any benefit to endocrine 
therapy. HER2+ tumors are treated with monoclonal antibody trastuzumab 
which binds to HER2, inhibits HER2 signaling, significantly improving the 
overall outcome of the disease. ER+ tumors are associated with the best 
therapeutic outcome, whereas triple negative (TN) breast cancer (ER-/PR-
/HER2-) correlate with the worst prognosis (Bertos and Park, 2011).  
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 Gene expression profiling studies added another layer to the 
characterization of breast cancer subtypes. They are classified as Luminal A, 
Luminal B, HER2-enriched basal-like, normal breast-like, and claudin-low. 
Claudin-low tumors exhibit mesenchymal phenotypes that are characterized 
by low expression of epithelial markers (E-cadherin, claudins and occludins), 
triple-negative status of luminal markers, and hormone receptors. However, in 
contrast to the expected poor prognosis predicted by the presence of EMT 
which causes tumor cell invasion and metastasis, claudin-low tumors are not 
associated with worse prognosis compared to luminal B, HER2-enriched or 
basal-like. Yet, claudin-low tumors are more resistant to chemotherapy, in line 
with the contribution of EMT to therapy resistance (Bill and Christofori, 2015). 
 It has been shown that in some cases of triple-negative breast tumors 
exhibit simultaneous expression of epithelial and mesenchymal markers in the 
core of the tumor which is histologically indistinguishable from neighboring 
epithelial cells (Yu et al., 2013). Co-expression of epithelial and mesenchymal 
markers is also implicated in claudin-low and basal-like breast cancers, 
indicating a “partial EMT” phenotype (Prat et al., 2010). These findings are 
consistent with the implicated role of partial EMT in cancer stemness and 
aggressiveness which indicates that partial EMT is more likely to occur rather 
than a full EMT in breast cancers (Davis et al., 2014; Tsai and Yang, 2013). 
 
1.2 Inducers of EMT 
 A plethora of extracellular stimuli can activate an EMT program during 
development, wound healing and malignant tumor progression. An EMT is 
triggered by soluble growth factors such as transforming growth factor-β 
(TGF-β), fibroblast growth factor (FGF), epidermal growth factor (EGF), 
insulin-like growth factor (IGF), hepatocyte growth factor (HGF), platelet-
derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) 
in a context-dependent manner (Lamouille et al., 2014). Epithelial cells 
respond to these ligands by activating receptor-mediated intracellular 
signaling pathways, such as TGF-β, EGF, FGF, Wnt, Notch and many others 
and cross-talk between these pathways regulate EMT process. For example, 
TGF-β/Smad pathway regulate EMT by cooperating with activated Ras kinase 
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pathway through receptor tyrosine kinases (RTKs) is required for 
maintenance of complete EMT (Zavadil and Bottinger, 2005). EMT can also 
be induced by hypoxia, cytokines and mechanical stress (Gjorevski et al., 
2012). 
1.2.1 TGF-β  signaling in EMT 
 TGF-β signaling controls cell behavior in many diverse processes, 
including cell proliferation, differentiation, apoptosis, hence tissue 
homeostasis during development and tissue regeneration. Upon TGF-β ligand 
binding, type I and type II TGF-β receptors interact and form a 
heterotetrameric complex, followed by phosphorylation of type I receptor. 
Activated type I TGF-β receptor leads to phosphorylation of receptor regulated 
Smad (R-Smad) proteins, Smad2 and Smad3. R-Smads form a complex with 
common-mediator Smad (Co-Smad), Smad4 and translocate to the nucleus to 
regulate the target gene expression by interacting with other transcriptional 
cofactors (Shi and Massagué, 2003; Zavadil and Bottinger, 2005). 
 The role of TGF-β in induction of EMT is shown in normal mammary 
epithelial cells with phenotypic change from cuboidal morphology to fibroblast-
like phenotype, with concomitant decrease of epithelial and upregulation of 
mesenchymal markers, with increased motility. This EMT is reversed upon 
removal of TGF-β (Miettinen et al., 1994). Further, it has been shown that 
TGF-β/Smad signaling induce transcription factor Snail (Hoot et al., 2008), 
which in return interacts with Smad3 and Smad4 to repress epithelial genes 
E-cadherin and occludin (Vincent et al., 2009).  TGF-β leads to a gradual 
increase of Zeb1 and Zeb2, which are required to repress E-cadherin 
expression during EMT, which is further controlled by MAPK signaling 
(Shirakihara et al., 2007). 
 TGF-β can also induce EMT through RhoGTPases, Pi3K and MAPK 
pathways, named as non-canonical TGF-β signaling.  RhoGTPases such as 
RhoA, Rac1 and Cdc42 drive cell migration and invasion by rearranging actin 
cytoskeleton and forming lamellipodia and filopodia, respectively (Yilmaz and 
Christofori, 2009). TGF-β induces mammalian TOR complex 1 and 2 
(mTORC1 and mTORC2) via activating AKT/PI3K pathway during EMT, 
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required for cell size, migration and an EMT phenotype, respectively 
(Lamouille et al., 2014). Additionally, TGF-β can activate Erk/MAPK pathway, 
which drives disassembly of adherens junctions and cell motility during EMT 
(Zavadil and Bottinger, 2005). 
 
1.3 Transcriptional and post-transciptional control in 
EMT 
 EMT is regulated by highly orchestrated networks of alternative spicing 
and transcriptional control mechanisms. The cooperation between 
transcriptional and post-transcriptional machinery contributes to the epithelial 
mesenchymal plasticity and deregulation drives malignant tumor progression 
(Lamouille et al., 2014). 
1.3.1 Transcriptional control of EMT 
 Extracellular signals activate an EMT program, regulate switches from 
epithelial to mesenchymal cell states through contribution of many 
transcription factors in tissue-specific manner. The transcription factor families 
such as Snail, includes zinc finger proteins (Snail and Slug), Zeb1 family 
(zinc-finger E-box binding Zeb1 and Zeb2) and Twist (basic helix-loop-helix 
proteins Twist1, Twist2, Id, E12, E47) are referred to as the master regulators 
of EMT process. These transcription factors are activated by various 
microenvironmental signals such as TGF-β, Wnt family proteins and Notch. 
These ligands activate several signaling pathways to regulate the initiation 
and maintenance phases of an EMT (Lamouille et al., 2014).  
 Snail1, Zeb1 and Twist1 can repress epithelial genes by interacting 
with the E-box DNA sequences, acting as an early inducer of EMT. They 
mediate transcriptional repression of E-cadherin, the most crucial step during 
EMT, by recruiting several epigenetic complexes (Dong et al., 2013; Dong et 
al., 2012; Herranz et al., 2008; Lin et al., 2010a; Peinado et al., 2004; Wang et 
al., 2007; Yang et al., 2010) (See chapter: Histone modifications during EMT). 
Further, they regulate EMT and cell motility through repression of other 
epithelial genes such as claudins and occludins and activate mesenchymal 
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gene expression such N-cadherin and several ECM proteins (Lamouille et al., 
2014).  
 Transcription factors are aberrantly induced during cancer progression. 
Snail and Twist1 are highly expressed, associated with repression of E-
cadherin in breast carcinoma (Cheng et al., 2001). High expression levels of 
Snail and Zeb2, correlated with low expression levels of E-cadherin in breast 
cancer (Elloul et al., 2005). Increased expression levels of Slug is associated 
with metastasis in human breast cancers (Martin et al., 2005). Zeb1 promotes 
metastasis in colorectal cancers by repressing cell polarity gene, Lgl2 
(Spaderna et al., 2008).  	 In addition to these transcription factors, large number of transcription 
factors are implicated in EMT and malignant tumor progression such as Sox4 
(Tiwari et al., 2013b), Prrx1 (Ocaña et al., 2012), Klf4 (Tiwari et al., 2013a) 
and many others. 
1.3.2 Alternative splicing in EMT 
Alternative splicing of mRNAs is a post-transcriptional mechanism, 
which leads to generation of different mRNA and protein isoforms. Extensive 
isoform changes are also implicated during EMT with alternative splice 
variants mutually exclusive to the epithelial and mesenchymal cell states 
during EMT (Brown et al., 2011; Eswarakumar et al., 2002; Pino et al., 2008).  
Fibroblast growth factor 2 (FGFR2) is spliced into two isoforms, exon 
FGFRIIIb is associated with the epithelial cells, while exon FGFRIIIc is 
specific to the mesenchymal cells, which are both tightly regulated during 
development (De Moerlooze et al., 2000; Eswarakumar et al., 2002). A switch 
from variant isoforms (CD44v) to the standard isoform (CD44s) of CD44, a 
cell surface marker, is required to drive EMT process. In addition, the CD44s 
isoform is highly expressed in high-grade human breast tumors (Brown et al., 
2011). A member of the Ena/VASP family, hMena (ENAH) spliced to 
hMena+11a is implicated as an epithelial marker in human pancreatic cancer 
cell lines (Pino et al., 2008). In addition, cadherin-associated protein p120 
catenin regulates RhoGTPases and cell motility by cell state specific splice 
variants. Epithelial cells expess short-length p120 isoforms, lack N-terminal 
domain, while mesenchymal cells express the full length transcript to repress 
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RhoA activity (Yanagisawa et al., 2008). It is shown that splicing of FGFR2, 
CD44, ENAH and p120-Catenin (CTNND1) is regulated by Epithelial Splicing 
Regulatory Proteins 1 and 2 (ESRP1 and ESRP2), master regulators of the 
epithelial-specific splicing process. The depletion of ESRP1 and ESRP2 
induced a switch from epithelial-specific isoforms to the mesenchymal state 
associated transcript variant induced an EMT, is rescued with ectopic 
expression of ESRP1 (Warzecha et al., 2009). In addition, RBFOX2 is a 
crucial regulator of the mesenchymal-specific splicing events (Venables et al., 
2013) and the ratio between ESRP1 or ESRP2 and RBFOX2 which is 
decreased during EMT, correlated with higher risk of metastasis in early 
breast cancer patients, indicating a potential biomarker for metastasis in 
breast cancer (Fici et al., 2017). In summary, highly coordinated events during 
mutually exclusive regulation of splicing variants in epithelial and 
mesenchymal cells provide important insights in the regulation of reversible 
cell states.  
 
1.4 Epigenetic regulation of EMT 
 
 In 1942, Waddington defined the term “epigenetics” as changes in 
phenotype without an effect on genotype. Later on, it was further clarified that 
inheritance of gene expression is transmitted by epigenetic mechanisms by 
modifying chromatin without any alterations to the genomic sequence. 
Enzymatic changes in the chromatin state may dictate a cell to alter its gene 
expression as well as epigenetic regulators. Euchromatin (open-chromatin) is 
associated with gene activity and heterochromatin (closed-chromatin) is 
correlated with gene repression. The epigenetic regulators refers to the 
covalent modifications on DNA or histones which can regulate gene 
expression and chromatin stability in a reversible manner (Allis and Jenuwein, 
2016). During EMT, cells can undergo multiple phenotypic transitions between 
epithelial and mesenchymal cell states regulated by genetic and epigenetic 
changes (Tam and Weinberg, 2013).  
1.4.1 DNA methylation/demethylation during EMT 
 DNA methylation is a crucial epigenetic process that regulates gene 
expression. DNA methylation is catalyzed by DNA methyltransferases 
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(DNMTs) by covalent transfer of methyl group to the 5th carbon position of the 
cytosine residues in CpG islands, called as 5mC (Bird, 2002). DNA 
methylation generally represses transcription exerting its function by 
interfering with the binding of transcription factors to their target sites or by 
regulating the recruitment of the methyl-CpG-binding proteins with their 
associated chromatin remodeling complexes (Robertson, 2005; Schubeler, 
2015). DNA methylation is a relatively stable epigenetic modification once it is 
established in somatic cells. However, it is dynamically regulated during early 
embryonic development and in tumor cells (Wolffe et al., 1999). 
 It has been shown that the promoter of the E-cadherin was silenced by 
hypermethylation in human breast and prostate carcinomas. Treatment with 
the demethylating agent 5-aza-2’-deoxycytidine partially restored the E-
cadherin expression levels (Graff et al., 1995). The inhibition of E-cadherin 
expression with the promoter hypermethylation, is restored by 5-aza-2’-
deoxycytidine in hereditary diffused gastric cancer (Grady et al., 2000). 
Similarly, loss of estrogen receptor α (ERα) gene was dependent on the 
hypermethylation of promoter regions in breast cancer cell lines and in 
primary human breast cancers (Lapidus et al., 1996; Ottaviano et al., 1994). It 
has been suggested that alterations of methylation levels on E-cadherin and 
ERα gene promoters start prior to the invasion and increase during later 
stages of tumor progression in human ductal breast carcinomas (Nass et al., 
2000). In addition, hypermethylation of miR-200 family promoter leads to 
upregulation of Zeb1 and Zeb2, associated with the mesenchymal phenotype 
and metastasis (Davalos et al., 2012) (Neves et al., 2010; Vrba et al., 2010).  
 It has been reported that during TGF-β-induced EMT, E-cadherin and 
collagen 1A1 genes indicated aberrant methylation patterns that can be 
reversed by the removal of TGF-β. In addition, TGF-β contributed to the 
induction of DNMTs. Inhibition of DNMTs reversed TGF-β-induced EMT in 
ovarian cancer cells (Cardenas et al., 2014). However, it has been suggested 
that genome-wide DNA methylation patterns are not altered dramatically 
during EMT in AML12 mouse hepatocytes. Rather, it is the histone 
modifications which exhibited significant changes (McDonald et al., 2011). 
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 These reports provided evidence for the role of DNA methylation and 
the removal of methylation by DNA demethylating agents that target DNMTs 
leads to passive dilution of methyl groups during replication. However, DNA 
methylation can be either passively lost during several rounds of replication in 
the absence of DNA methylation maintenance machinery or by the active 
DNA demethylation enzymes. Ten-eleven translocation (TET) family enzymes 
contribute to active DNA demethylation by sequentially oxidizing 5-
methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine 
(5fC), and 5-carboxylcytosine (5caC). Decarboxylation of 5caC, followed by 
conversion to unmethylated cytosines is mediated by TDG/BER pathway 
(Cimmino et al., 2011). It has been suggested that the depletion of TET family 
enzymes and TDG act as molecular blocks in MET by inhibiting demethylation 
of miR-200 family and impairs iPSC reprogramming from MEFs (Hu et al., 
2014). It has been shown that miR-22 overexpression leads to 
hypermethylation of miR-200 promoter via repressing TET hydroxylases 
which in return induces Zeb1/2 and promoting EMT, stemness and metastasis 
(Song et al., 2013).  
 Further, developing new methods to detect genome-wide DNA-
methylation turnover kinetics can be important to interpret the stability of 
modified cytosines which might be regulated by active DNA demethylation 
machinery (Schubeler, 2015) and can give important insights especially in 
establishing cell plasticity mechanism such as EMT.  
1.4.2 Histone modifications during EMT 
 Histones serve as the basic components of chromatin structure 
together with DNA (nucleosome), regulate heritable chromatin states and 
gene expression by chemical modifications on the histone tails. Histones are 
modified by various covalent modifications at different aminoacid residues 
such as acetylation and methylation of lysines, methylation of arginines, and 
phosphorylation of serines and threonines (Turner, 2007). These 
modifications are dynamically regulated and reversed by deacetylases, 
demethylases and phosphatases. In general terms, acetylation of histones is 
associated with the active gene transcription and deacetylation is implicated in 
the gene repression, whereas, methylation and demethylation can act as the 
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activator or repressor of gene transcription depending on the amino acid 
residue (Bannister and Kouzarides, 2011). 
1.4.2.1 Histone methylation  
 Histones are methylated by histone methyltransferases (HMTs) which 
are classified according to their substrate specificity as lysine or arginine 
methyltransferases. Lysines that are mainly methylated on histone H3 (K4, 
K36, K79) are associated with the active gene transcription, and H3 (K9, K27, 
and K20) are correlated with transcriptional repression (Kouzarides, 2007). 
Lysine residues on histones can be mono-, di-, or tri-methylated by SET 
(SU(VAR) 3-9, the Polycomb-group (PcG) protein Enhancer of Zeste and the 
trithorax-group (TrxG) protein Trithorax) domain containing enzymes such as 
G9a, EZH1/2, and SUV39H1/H2 and others (Zhang and Reinberg, 2001). 
Polycomb group (PcG) complexes 
 PcG complexes that are involved in transcriptional repression consist of 
two major complexes, polycomb repressor complex 1 (PRC1) and 2 (PRC2). 
The mammalian PRC2 contains three core components: enhancer of zeste 1 
or 2 (EZH1/2), embryonic ectoderm development (EED), and suppressor of 
zeste 12 (SUZ12). EZH1 and EZH2 catalyze mono-, di- and trimethylation of 
H3K27 residues. The deposition of H3K27me3 recruits the PRC1 complex 
which contributes to the maintenance of the gene silencing by catalyzing 
monoubiquitination of H2A on K119 (H2AK119ub1) (Di Croce and Helin, 
2013). 
 The elevated expression levels of Ezh2 is implicated in many 
carcinomas such as breast cancer (Collett et al., 2006; Kleer et al., 2003), 
BRCA1-deficient breast cancer (Puppe et al., 2009), prostate cancer 
(Varambally et al., 2002) which are associated with tumor invasiveness, 
metastasis and correlated with an EMT gene signature. PRC2 is involved in 
EMT and tumor progression by repressing the E-cadherin expression (Cao et 
al., 2008). Additionally, it has been suggested that PRC2 contributes to the 
silencing of the E-cadherin expression thereby inducing EMT by direct 
interaction with several EMT-associated transcription factors. For example, 
transcription factor Snail recruits the PRC2 complex by directly interacting 
with Suz12 and Ezh2 on the E-cadherin promoter. Increased H3K27me3 mark 
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on the E-cadherin promoter leads to the repression of the E-cadherin 
expression (Herranz et al., 2008). Snail can repress E-cadherin by recruiting 
G9a and SUV39H1 methyltransferases (Dong et al., 2013; Dong et al., 2012). 
It has been shown that Ezh2 is the direct target of Sox4 and is upregulated 
during TGF-β-induced EMT. The depletion of Ezh2 blocked TGF-β-induced 
EMT and metastatic colonization. Interestingly, Ezh2 can deposit H3K27me3 
marks on many EMT-related gene promoters that are associated with the 
tumor invasiveness and distant metastasis (Figure 5) (Tiwari et al., 2013b). 
Suz12 overexpression is also indicated in the induction of EMT and 
metastasis by regulating transcriptional repression of epithelial genes such as 
E-cadherin and Klf2 in human gastric cancers (Xia et al., 2015). In addition, 
another core component of the PRC2 complex, EED is upregulated during 
TGF-β-induced EMT through recruitment of Ezh2 and H3K27me3 marks. The 
depletion of EED antagonized the expression of EMT-relevant genes such as 
E-cadherin, Zeb1, Zeb2 and miR-200 family in lung and colon cancer cells 
(Figure 5) (Oktyabri et al., 2014). However, functional role of PRC2 is highly 
context-dependent due to the cooperation of the PRC2 components with 
oncogenic signaling factors in several cancers (De Raedt et al., 2014). For 
instance, KRAS-driven tumors undergo autonomous EMT, with the 
simultaneous inactivation of the PRC2 components (Ezh2 and EED) and 
Trp53 gene, which shows a barrier function by PRC2 during EMT (Serresi et 
al., 2016).  
 It is important to note the co-existence of the repressive and active 
methylation marks such as H3K27me3 and H3K4me3 creates poised 
chromatin (bivalent domains) which maintains repression as the default state 
and activates with the appropriate signals in embryonic stem cells (Bernstein 
et al., 2006). These bivalent domains can contribute to EMT/MET plasticity by 
enabling rapid changes in chromatin states in response to the EMT inducing 
signals. Indeed, it has been indicated that plastic non-cancer stem cell (CSC) 
populations generate CSC populations that exhibit more mesenchymal 
phenotype by maintaining the poised chromatin state of the Zeb1 promoter 
that is activated upon TGF-β induction (Chaffer et al., 2013). It has been also 
shown that Twist1-induced EMT leads to the increased bivalent domains on 
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the important EMT-related gene promoters and contributes stemness (Malouf 
et al., 2013).  
 
 
Figure 5: Cooperation of histone modifiers with transcription factors to modify 
E-cadherin expression. Polycomb group complexes (PcG) (pink), histone 
demethylases (yellow), cooperate with transcription factors to regulate the E-
cadherin promoter. 
 
 Initial deposition of H3K27me3 marks by the PRC2 complex signals for 
the recruitment of PRC1 complex to maintain the inactive state and 
transcriptional memory. H3K27me3 marks are recognized by the chromobox 
homologue (CBX) proteins and nuclear localization is mediated by the RING 
finger domain containing proteins BMI1, RING1 and RNF2 of PRC1 complex 
(Mills, 2010). It has been reported that BMI1 overexpression induces EMT 
and stemness. The depletion of BMI1 leads to the reversion of EMT, reduced 
stemness and increased drug sensitivity in breast cancer cells (Paranjape et 
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al., 2014). In addition, it has been shown that Twist1 induced EMT and 
stemness by directly regulating the BMI1 in head and neck squamous cell 
carcinoma (HNSCC) (Figure 5) (Yang et al., 2010). 
 These findings indicate that interaction between the PRC1 and PRC2 
complexes with various EMT-relevant factors can contribute to the EMT, 
stemness and tumor aggressiveness by changing the chromatin 
conformations. 
1.4.2.2 Histone demethylation 
 Histone methylation has been long interpreted as a stable modification. 
It has been unclear whether the histone methylation is a dynamically 
regulated process through the antagonizing enzymes. Later on, it was shown 
that the Lysine specific demethylase (Lsd1) acts as a transcriptional 
corepressor by catalyzing the removal of mono- and di-methylation marks on 
H3K4 (Shi et al., 2004). After the discovery of the dynamic regulation of 
histone methylation by counteracting histone demethylases, a plethora of 
experiments showed the involvement of these enzymes in cellular plasticity 
such as EMT (Lin et al., 2010a; Lin et al., 2010b). It has been revealed that 
Snail represses the epithelial gene promoters such as E-cadherin, CLDN7, 
and KRT8 via direct interaction with Lsd1. Lsd1 reduces the active H3K4m2 
mark, thereby contributes to the maintenance of the transcriptional repression 
of these epithelial genes (Lin et al., 2010a). Snail1 suppresses E-cadherin 
with its SNAG domain that has a similarity with the histone H3 tail to interact 
with the amine oxidase domain of Lsd1 and form a complex together with 
CoREST (Figure 5) (Lin et al., 2010b). It has been shown that Lsd1 along with 
Snail is required in the SLUG mediated mammary epithelial cell plasticity, 
lineage commitment by contributing to the repression of lineage-specific gene 
promoters (Phillips et al., 2014). Indeed, Lsd1 inhibitor Parnate, blocked the 
interaction of Lsd1 with the SNAG domain of Slug, reverted EMT, reduced 
tumor cell motility and invasiveness both in vitro and in vivo (Ferrari-Amorotti 
et al., 2014; Ferrari-Amorotti et al., 2013). 
 High expression levels of Lsd1 were observed in ER- and PR- breast 
cancers and correlates with tumor aggressiveness (Lim et al., 2010). This 
implicates a possible role for the deregulation of Lsd1 during EMT. Indeed, it 
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has been shown that Lsd1 induces EMT by catalyzing the removal of 
H3K4me3 mark from the E-cadherin promoter, which causes an induction in 
the mesenchymal markers N-cadherin, Vimentin and MMP-2 in ovarian 
cancer cells (Li et al., 2016). In addition, the inhibition of Lsd1 by Pargyline 
(Lsd1 inhibitor) inhibits EMT by restoring the E-cadherin expression and 
downregulating N-cadherin and Vimentin in prostate cancer (Wang et al., 
2015). 
 Lsd1 is a component of various corepressor complexes (Lee et al., 
2005; Shi et al., 2005; Wang et al., 2007). Lsd1 also forms a complex with the 
Mi-2/nucleosome remodeling and deacetylase (NuRD), inhibits in vitro tumor 
cell invasion, and metastasis in vivo by negatively regulating EMT via 
inhibiting TGF-β as a downstream target (Wang et al., 2009). In another study 
it has been shown that Lsd1 is upregulated during TGF-β-induced EMT, 
accompanied by genome-wide loss of the repressive marks H3K9me2 and 
gain of the active marks H3K4me3 in a reversible manner depending in part 
on Lsd1. However, the depletion of Lsd1 did not affect the initiation of EMT in 
AML12 hepatocytes, hence Lsd1 was regulated as the downstream of the 
TGF-β-induced EMT (McDonald et al., 2011). This finding is in concert with 
the functional role of Lsd1 in the removal of repressive H3K9 methylation 
marks and the activation of target genes depending on the interaction partner 
(Metzger et al., 2005). These results suggest that Lsd1 is a crucial player 
during EMT by interacting with several transcription factors and corepressor 
complexes to either supress or to activate EMT-related target genes. 
1.4.2.3 Histone acetylation 
 Histone acetylation leads to a switch between permissive and 
repressive chromatin states (Eberharter and Becker, 2002). Histone 
acetyltransferases (HATs) catalyze the acetylation of lysine residues, which 
neutralizes the positive charges of histones and leads to open chromatin 
configuration by reducing its binding potential with the negatively charged 
DNA (Glozak and Seto, 2007). Several multiprotein complexes of coactivators 
with HAT activity catalyze the acetylation of histones. They are mainly 
classified into 3 groups, GNAT, CBP/p300, and MYST (Kouzarides, 2007; 
Roth et al., 2001). 
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 HATs are mostly associated with the induction of EMT and cancer cell 
metastasis by acetylating the transcription factor Snail (Chang et al., 2017; 
Hsu et al., 2011). The induction of EMT in lung tumor-associated osteoblast 
cells enhances the Runx2 and Snail expression. Further, it has been shown 
that the increased Runx2 recruits p300 to the Snail promoter, which has a 
binding site for p300, hence induces the Snail expression (Hsu et al., 2011). 
The acetylation of Snail by p300 is also known to induce an EMT in lung 
cancer cells (Chang et al., 2017). In addition, p300 is overexpressed in 47% 
of the HCC patient samples, accompanied with an EMT-like process.  Further, 
depletion of p300 in HCC cell lines led to an increase in E-cadherin, 
associated with the Snail, Twist1 and HIF-1α downregulation, indicating a 
MET phenotype (Yokomizo et al., 2011). However, it has been suggested that 
p300 positively regulates the E-cadherin expression by interacting with the E-
cadherin promoter together with the other factors and suppresses the 
metastatic potential of breast cancer cells (Liu et al., 2005). MOF, a member 
of MYST family is associated with the epithelial state and is downregulated 
during EMT. MOF can acetylate Lsd1 only in epithelial cells, interfering with 
the Lsd1-mediated methylation of the epithelial gene promoter thereby 
blocking EMT and tumor invasion (Luo et al., 2016). 
 Although, Snail is mostly associated with the transcriptional repression 
of the E-cadherin (Cano et al., 2000; Herranz et al., 2008; Peinado et al., 
2004). It has been indicated that Snail can act as a transcriptional activator of 
its target genes during EMT. Snail mediates the acetylation and induction of 
its target genes such as ERCC1 and IL8 by recruiting the CREB-binding 
protein (CBP) to their promoters. Interestingly, this result indicates that Snail 
contributes to EMT and metastasis by being not only as a transcriptional 
repressor of the adhesion proteins, but also by activating the genes which are 
involved in tumor microenvironment remodeling (Hsu et al., 2014). 
1.4.2.4 Histone deacetylation 
 Acetylation of histones is a reversible process mediated by histone 
deacetylases (HDACs). HDACs remove the acetyl groups, allowing 
compaction of the chromatin and prevent accessibility of transcriptional 
machinery, mostly correlates with the transcriptional repression (Glozak and 
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Seto, 2007). HDACs are divided into two families and four classes according 
to their sequence similarities and cofactor dependencies. In humans, HDAC1, 
-2, -33 and 8 (class I); HDAC4, -5,-6,-7,-9 and -10 (class II); and HDAC11 
(class IV) belong to the classical HDAC family. The second family is NAD+-
dependent sirtuins (SIRT1-7, class III) which have no sequence similarities 
with the classical HDAC family (Yang and Seto, 2007). HDACs mostly exert 
their function within the multimeric complexes, often with the other family 
members. For example, HDAC1 and HDAC2 are involved in NuRD, Sin3a 
and CoREST complexes. Complexes are crucial to bring stability and recruit 
the HDACs to the specific target genes for the transcriptional regulation 
(Bannister and Kouzarides, 2011). 
HDAC inhibitors interfere with the enzymatic activity of HDACs, induce 
hyperacetylation of histones and therefore transcriptional activation of the 
target genes. HDAC inhibitors gained great attention in cancer therapy due to 
their pro-apoptotic, anti-proliferative and anti-angiogenic effects (Mottamal et 
al., 2015). In addition, several studies showed the effect of HDAC inhibitors 
during EMT. Some reports showed that pan-HDAC inhibitors such as 
Trichostatin A (TSA) and Suberoylanilide hydroxamic acid (SAHA) induced an 
EMT phenotype associated with the increased mesenchymal genes vimentin, 
N-cadherin and fibronectin in the prostate cancer cells (Kong et al., 2012). 
Similar results were observed in the nasopharygeal, colon and liver carcinoma 
cell lines (Jiang et al., 2013). However, it has been implicated that HDAC 
inhibition led to a significant inhibition on the hepatocellular carcinoma 
metastasis (Coradini et al., 2004). In addition, the inhibition of HDACs has 
been implicated in the reversion of mesenchymal cells to the epithelial state, 
either partially in triple negative breast cancer (TNBC) cell lines (Jiang et al., 
2013) or fully in breast (Srivastava et al., 2010), ovarian, bladder and 
pancreatic cancer cells (Luo et al., 2016). Interestingly, the intermediate EMT 
state reverted back to the epithelial state as detected by increased E-cadherin 
promoter activity and more potently by HDAC class I inhibitors (Luo et al., 
2016), indicating EMT states may dictate the differences in response to the 
HDAC inhibition during EMT. Additionally, E-cadherin expression was 
restored with the concomitant decrease in Zeb1, with the increased drug 
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sensitivity to the gemcitabine treatment by HDAC class I inhibitor 
(mocetinostat) in pancreatic cancer cells (Meidhof et al., 2015). The 
contradictory findings about the effect of HDAC inhibitors on EMT can be due 
to the pleiotropic effects of pan-HDAC inhibitors. In addition, the given findings 
of the potency of HDAC class I inhibitors in reverting the mesenchymal state 
to the epithelial state can give a hint that the regulation of EMT may depend 
on more to the activity of HDACs within the corepressor complexes.   
HDACs, in particular, HDAC1 and HDAC2 predominantly function as 
part of the several stable multimeric complexes such as CoREST, Sin3a and 
NuRD, enabling the recruitment of HDACs to the specific target sites 
(Denslow and Wade, 2007; Grozinger and Schreiber, 2002; Hayakawa and 
Nakayama, 2011). Indeed, Snail silences E-cadherin by recruiting corepressor 
complex Sin3a/HDAC1 and HDAC2. In addition, the recruitment of HDAC1/2-
containing Mi-2/nucleosome remodeling and deacetylase (NuRD) complex by 
master regulators of EMT, such as Snail (Fujita et al., 2003) and Twist 
(Bannister and Kouzarides, 2011), to the E-cadherin gene promoter 
contributes to the silencing of the E-cadherin (Figure 6). 
 NuRD complexes can be formed by various combinations of different 
subunits to provide functional specificity, such as HDAC1 and HDAC2 
containing Methyl-CpG-binding domain 3 (Mbd3)/NuRD complex or 
Mbd2/NuRD.  (Hendrich and Tweedie, 2003; Lai and Wade, 2011). Mbd3 
lacks the ability to bind methylated DNA regions might indicate that different 
combinations of NuRD complex can contribute to an EMT due to the different 
substrate specificities. 
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Figure 6: Cooperation of histone modifiers with transcription factors to modify 
E-cadherin expression. Histone deacetylases (blue) cooperate with transcription 
factors to regulate the E-cadherin promoter. 
 
1.4.2.5 miRNAs and lncRNAs in EMT 
 MicroRNAs are approximately 22 nucleotide long non-coding RNAs 
(lncRNAs) that post-transcriptionally regulate gene expression (Bartel, 2004). 
Different mRNAs can be targeted by one miRNA, yet several miRNAs can 
target the same mRNA as well (Friedman et al., 2009). miRNAs act as 
molecular switches to regulate developmental processeses (Mendell, 2005) 
and EMT (Gregory et al., 2008). miR-200 family is associated with the 
epithelial phenotype, blocks TGF-β-induced EMT and the induced 
overexpression of the miR-200 family converts mesenchymal canine kidney 
cells (MDCK) to the epithelial state (Gregory et al., 2008). In addition, the 
enhanced expression of the miR-200 family induced a MET, identified by the 
upregulation of E-cadherin and the downregulation of Zeb1 and Zeb2 in the 
mesenchymal 4TO7 cells (Korpal et al., 2008). However, Zeb1 can also 
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suppress miR-200 family by binding to the specific sites on their promoters 
during TGF-β-induced EMT and this reciprocal feedback loops are important 
regulators of the cell migration and invasion in breast cancer cell lines (Burk et 
al., 2008). These results indicate that reciprocal feedback loops between 
miRNAs and transcription factors can regulate the plasticity of EMT process. 
In addition to miRNAs, long non-coding RNAs (lncRNAs), length of more than 
200 nucleotides, are implicated during EMT. LncRNA HOTAIR is highly 
expressed in many different cancer types and correlated with the lymph node 
metastasis, depletion of lncRNA HOTAIR induces a MET (Xu et al., 2013). 
LncRNA-ATB is induced by TGF-β in normal liver cell line as well as in breast 
and colorectal cancer cell lines. LncRNA-ATB can physically interact with the 
miR-200 family, acts as a competitive endogenous RNA to regulate Zeb1 and 
Zeb2, leads to the induction of EMT and tumor cell invasion and metastasis. 
However, lncRNA-ATB induces metastasis by partially depending on the 
interaction with the miR-200 family. LncRNA-ATB regulates the metastatic 
colonization through IL-11/STAT3 pathway by causing the autocrine induction 
of IL-11 (Yuan et al., 2014). It is also reported that lncRNA-LET prevents EMT 
and Wnt/β-catenin pathway as well as cell migration and invasion (Liu et al., 
2016). 
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2 Aim of the study 
Epithelial-mesenchymal transition (EMT) and its reverse process 
mesenchymal-epithelial transition (MET) is an example of cell plasticity which 
is implicated as a crucial mechanism during tumor invasion and metastatic 
dissemination. However, the underlying mechanisms that regulate dynamic 
switches between epithelial and mesenchymal cell states during tumor 
progression are still poorly understood. The plastic nature of EMT implies a 
key role for the rearrangement of chromatin states that are regulated by 
epigenetic modifiers. Therefore, in this study, we aimed to elucidate the key 
epigenetic players which contributed to the epithelial-mesenchymal plasticity 
as well as tumor progression and metastatic outgrowth.  
To answer these questions, we generated an in vitro irreversible EMT 
model by manipulating specific medium conditions to identify the de novo 
established epigenetic modifications that induce and maintain the 
mesenchymal cell state. We compared these irreversible EMT cells to the 
transforming growth factor β (TGF-β)-induced reversible EMT cells to 
understand the epigenetic differences between transient and fixed 
mesenchymal cell states.  
This study will provide us important understandings to discover new 
therapeutic approaches to target cell state transitions during breast cancer 
progression. Hence, by interfering with several epigenetic modifiers, we will 
be able to target wide-range of gene networks that are responsible in tumor 
growth and metastasis formation.  
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3 Results 
3.1 A critical role of histone deacetylases, Mbd3/NuRD 
and Tet2 hydroxylase in epithelial-mesenchymal cell 
plasticity and tumor metastasis 
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3.1.1 Summary 
While a critical role of epigenetic modifiers and their specific chromatin 
modifications has been demonstrated during an EMT, it has remained elusive 
whether epigenetic control differs between the dynamic cell state transitions of 
a reversible EMT and the fixed differentiation status of an irreversible EMT. 
We have employed varying EMT models of murine breast cancer cells to 
identify the key players establishing cell state transitions during a reversible 
and an irreversible EMT. We demonstrate that the Mbd3/NuRD complex and 
the activities of histone deacetylases (HDACs) and Tet2 hydroxylase keep the 
cancer cells in a mesenchymal state. Their pharmacological inhibition and/or 
RNAi-mediated ablation lead to a mesenchymal-epithelial transition (MET) 
and the repression of metastasis formation by mesenchymal breast cancer 
cells. 
3.1.2 Significance 
An epithelial-mesenchymal transition (EMT) represents a basic 
morphogenetic process of high cell plasticity underlying embryogenesis, 
wound healing and cancer metastasis and drug resistance. It involves a 
profound transcriptional reprogramming of cells, however, the role of 
epigenetic regulation in differentiating a reversible EMT from an irreversible 
EMT has remained elusive. Here, we demonstrate a critical role of the 
Mbd3/NuRD complex together with histone deacetylases (HDACs) and Tet2 
hydroxylase in maintaining a stable mesenchymal phenotype of murine breast 
cancer cells. Combinatorial interference with their functions represses primary 
tumor growth and breast cancer metastasis, making these epigenetic 
modifiers attractive targets for cancer therapy. 
3.1.3 Highlights 
o Reversible and irreversible EMT differ in gene expression and 
epigenetic regulation 
o HDACs, Mbd3 and Tet2 maintain an irreversible EMT 
o HDACs, Mbd3 and Tet2 act in an additive manner to maintain a 
mesenchymal cell state 
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o Inhibition of HDACs and/or Mbd3 and Tet2 represses tumor growth and 
metastasis 
3.1.4 Introduction 
An epithelial-mesenchymal transition (EMT) is a critical morphogenetic 
process during embryonic development and wound healing (Baum et al., 
2008; Hanahan and Weinberg, 2011; Kalluri and Weinberg, 2009; Nieto, 
2011; Thiery, 2002; Yang and Weinberg, 2008). The dynamic transitions from 
an epithelial to a mesenchymal cell state have also been shown to promote 
cancer cell stemness and tumorigenicity, cancer cell invasion, metastatic 
dissemination and drug resistance (Baum et al., 2008; Diepenbruck and 
Christofori, 2016; Kalluri and Weinberg, 2009; Nieto, 2011; Thiery, 2002). The 
profound changes in gene expression and the high cell plasticity 
accompanying the dynamic processes of an EMT and its reversion, a 
mesenchymal-epithelial transition (MET), imply a key role of the 
rearrangement of chromatin states by epigenetic modifications, including 
changes in gene-specific histone acetylation, histone methylation and DNA 
methylation (Bedi et al., 2014; McDonald et al., 2011; Tam and Weinberg, 
2013). While the importance of epigenetic modifications and the respective 
chromatin modifying enzymes has been documented (McDonald et al., 2011; 
Tam and Weinberg, 2013), the actual contribution of epigenetic changes to 
epithelial-mesenchymal cell plasticity, notably to the reversibility or 
irreversibility of an EMT, is poorly understood. 
Histone deacetylases (HDACs) catalyze the removal of acetyl groups 
from lysine residues of histones, leading to chromatin condensation and 
repression of gene expression (Glozak and Seto, 2007; Haberland et al., 
2009). The inhibition of HDAC activity has been implicated in the conversion 
of mesenchymal cells into an epithelial state in breast, ovarian, bladder and 
pancreatic cancer cells (Srivastava et al., 2010; Tang et al., 2016; Tate et al., 
2012). HDACs, in particular HDAC1 and HDAC2, predominantly function as 
components of stable multi-protein complexes, including CoREST, Sin3a and 
NuRD, and thereby are recruited to specific target genes (Denslow and Wade, 
2007; Grozinger and Schreiber, 2002; Hayakawa and Nakayama, 2011). In 
the context of an EMT, the HDAC1/2-containing NuRD complex is bound by 
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the EMT transcription factors Snail and Twist and directed to the promoter 
region of the E-cadherin (Cdh1) gene to silence its expression (Fu et al., 
2011; Fujita et al., 2003). 
NuRD complexes can be formed by various combinations of different 
subunits to provide functional specificity, an example being the HDAC1 and 
HDAC2-containing Methyl-CpG-binding domain 3 (Mbd3)/NuRD complex 
(Hendrich and Tweedie, 2003; Lai and Wade, 2011). Mbd3 is a non-
enzymatic component of the Mbd3/NuRD complex with critical functions; its 
genetic deletion in mice causes early embryonic lethality (Hendrich et al., 
2001) and defects in lineage commitment of embryonic stem (ES) cells (Kaji 
et al., 2006; Kaji et al., 2007). Underscoring its crucial function in regulating 
cell plasticity, the Mbd3/NuRD complex serves as a molecular block in the 
rather inefficient reprogramming of mouse embryonic fibroblasts (MEFs) to 
induced pluripotent stem (iPS) cells; the depletion of Mbd3 allows a more 
efficient conversion of MEFs into iPS cells (Rais et al., 2013).  
Mammalian Mbd3 is the only Mbd family protein that is not able to 
recognize methylated CpG dinucleotides due to an amino acid change in the 
Mbd domain (Fraga et al., 2003; Hendrich and Tweedie, 2003; Saito and 
Ishikawa, 2002). It has been reported that Mbd3 is able to recognize 5-
hydroxymethylcytosine (5hmC) sites and recruit Mbd3/NuRD to these sites in 
mouse ES cells by binding to Tet1 (Yildirim et al., 2011), a member of the Tet 
hydroxylase family. Tet1, 2 and 3 hydroxylases contribute to active DNA 
demethylation by catalyzing the sequential oxidation of methylated cytosines 
(5mC) to 5-hydroxymethylcytosine (5hmC) to 5-formylcytosine (5fC) to 5-
carboxylcytosine (5caC), followed by the latter’s decarboxylation to 
unmodified cytosine (Tahiliani et al., 2009); (Cimmino et al., 2011). However, 
it has been also suggested that Mbd3-binding to DNA does not depend on 
5hmC (Baubec et al., 2013). On the other hand, Tet hydroxylases have been 
implicated in the initiation of a MET that is a prerequisite for MEFs to undergo 
iPS cell reprogramming (Hu et al., 2014); (Li et al., 2010; Samavarchi-Tehrani 
et al., 2010). However, the details of the functional contributions of the 
Mbd3/NuRD complex and Tet hydroxylases to pathophysiological cell state 
transitions and to an EMT remain largely unknown. Here, using cellular 
		 40	
models of an irreversible and a reversible EMT we have delineated the central 
role of the Mbd3/NuRD complex and of Tet2 hydroxylase in the maintenance 
of the mesenchymal state of murine breast cancer cells in vitro and primary 
tumor growth and metastasis in vivo. The results underscore a critical role of 
the Mbd3/NuRD complex and Tet hydroxylases in regulating epithelial-
mesenchymal plasticity and highlight them as therapeutic targets to interfere 
with metastatic breast cancer. 
3.1.5 Results 
3.1.5.1 Generation of an irreversible EMT system 
To investigate the dynamic transitions underlying a reversible EMT as 
compared to an irreversible EMT, we set out to establish an in vitro model 
system, which after undergoing an EMT lacked the ability to revert to an 
epithelial cell state. As a model for a reversible EMT we used Py2T murine 
epithelial breast cancer cells which upon treatment with TGFβ for >10 days 
undergo a full EMT, while when depleted of TGFβ readily convert back to their 
epithelial state (Waldmeier et al., 2012). Starting with Py2T cells, an 
irreversible EMT system was established by culturing them for 3 months in 
mammary epithelial growth medium (MEGM) in the presence of different 
concentrations of fetal bovine serum (FBS) (adapted from (Dumont et al., 
2008). Over time, a subset of Py2T cells acquired a mesenchymal cell 
morphology and, upon serial passaging, these subsets of cells retained their 
mesenchymal cell morphology. Individual mesenchymal phenotype cells were 
then isolated and expanded as cell clones that stably maintained their 
mesenchymal phenotype in basal medium (referred to as M clone cells M1, 
M2, and M3; Figure 1A,B). In contrast, long-term TGFβ-treated Py2T cells 
(referred to as Py2T-LT cells) reverted back to their epithelial state when 
TGFβ was withdrawn from the culture medium (referred to as Py2T-LT MET 
cells; Figure 1B). 
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Figure 1. In vitro characterization of irreversible EMT cells (M clone cells) (A) 
Scheme of the generation of an irreversible EMT system (M clone cells). (B) Phase-
contrast microscopy of Py2T cells, Py2T cells treated for >20days with TGFβ (Py2T-
LT), Py2T-LT cells upon TGFβ withdrawal (Py2T-LT MET), and M1, M2, and M3 
clone cells. Scale bar, 100µm. (C) Expression of E-cadherin (E-cad), fibronectin 
(Fn1), Snail, Zeb1, Twist1 was determined by quantitative RT-PCR in Py2T, Py2T-
LT, and Py2T-LT MET cells and in M1, M2, and M3 clone cells. Fold changes are 
related to expression levels in Py2T cells. (D) Expression of fibronectin (Fn1), N-
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cadherin (N-cad), E-cadherin (E-cad), and Vimentin (Vim) was determined by 
immunoblotting in Py2T, Py2T-LT, and Py2T-LT MET cells and in M1, M2, and M3 
clone cells. Immunoblotting for GAPDH was used as a loading control. (E) 
Immunoflorescence microscopy analysis of changes in the localization and 
expression levels of marker proteins in Py2T, Py2T-LT, and Py2T-LT MET cells and 
M1, M2, and M3 clone cells. Cells were stained with antibodies against the epithelial 
marker E-cadherin (E-cad) and the mesenchymal marker vimentin (Vim). DAPI was 
used to visualize nuclei. Scale bar, 50µm. Data are displayed as mean ± SEM. 
Statistical values were calculated using a paired, two-tailed t-test. *, P < 0.05; **, P < 
0.01, ***; P < 0.001; ****, P < 0.0001. 
 
To characterize whether M clone cells had undergone a bona fide 
EMT, we examined the expression of EMT markers by quantitative RT-PCR in 
irreversible EMT cells (M clones) compared to reversible EMT cells (Py2T-
LT). In M clone cells, the mRNA levels of genes associated with a 
mesenchymal state, such as fibronectin (Fn1), Snail, Zeb1 and Twist1, were 
continuously expressed at high levels, whereas epithelial genes, such as E-
cadherin (E-cad), were found at low levels throughout. In contrast, upon TGFβ 
withdrawal Py2T-LT cells regained the expression of E-cad and lost the 
expression of Fn1, Snail, Zeb1 and Twist1 (Figures 1C). Immunoblotting 
analysis further confirmed the hallmarks of an EMT in M clone cells. The 
protein levels of the mesenchymal markers Fn1, N-cadherin (N-cad) and 
vimentin (Vim) were high, while the protein levels of E-cad were low. In Py2T 
cells treated with TGFβ, expression of the mesenchymal marker proteins was 
high, whereas removal of TGFβ led to a loss of mesenchymal marker 
expression and an upregulation of E-cad protein expression (Figure 1D). 
Finally, immunofluorescence microscopy analysis revealed that M clone cells 
maintained their mesenchymal state by expressing Vim and lacking E-cad at 
the cell membranes, as did Py2T-LT cells. Py2T-LT MET cells lost Vim 
expression and re-expressed E-cad at the cell membranes (Figures 1E). 
Altogether, these results show that TGFβ-induced Py2T-LT cells revert from a 
mesenchymal state back to an epithelial state upon withdrawal of TGFβ, while 
M clone cells sustain their mesenchymal phenotype in basal culture 
conditions.  
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Next generation RNA sequencing identified 6624 genes differentially 
expressed between Py2T-LT cells and M clone cells, suggesting that the 
irreversible M clone cells significantly differ from reversible Py2T-LT cells, 
although they both originated from Py2T cells (data not shown). 
 
3.1.5.2 M clone cells are highly tumorigenic and 
metastatic 
Next, we assessed the tumorigenic potential of Py2T-LT and M clone cells by 
orthotopic transplantation into the mammary fat pads of immunodeficient NOD 
scid gamma (NSG) mice. M1 and M3 clone cells showed a significantly faster 
tumor growth rate than Py2T-LT cells (Figure 2A). Immunofluorescence 
microscopy analysis showed a low E-cad and high Vim expression (Figure 
2B), indicating that both Py2T-LT and M clone cells formed mesenchymal 
phenotype tumors. Almost all mice transplanted with M clone cells developed 
macroscopic lung metastases, while only 50% of the mice transplanted with 
Py2T-LT cells showed few microscopic metastatic lesions (Figure 2C). Upon 
tail vein injection of Py2T-LT, M1 and M3 clone cells, all mice developed 
metastasis, however, the M clone cells seeded a strikingly higher number of 
metastases and larger metastatic lesions in the lungs compared to Py2T-LT 
cells (Figure 2D,E).  
We next assessed the tumor initiation potential of the M clone cells and 
Py2T-LT cells by orthotopic injection of limiting dilutions of cells into 
immunodeficient BALB/c Rag2-/- common γ receptor-/- (RG) mice. M clone 
cells exhibited a significantly higher and faster tumor-forming capability than 
Py2T-LT cells (Figure 2F), and all tumors arisen from M clone cells could be 
serially transplanted (Figure 2G). Taken together, the data demonstrate a 
higher ability of irreversible EMT cells to initiate tumors and to colonize the 
lung as compared to reversible EMT cells. 
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Figure 2. Tumorigenicity of irreversible M clone cells (A) Primary tumor growth in 
the mammary fat pad of female immunodeficient NOD scid gamma (NSG) mice 
transplanted with 105 cells of Py2T-LT cells and M1 and M3 clone cells. Data are 
displayed as mean tumor volumes ± SEM. (B) Immunoflorescence staining of tumors 
formed by Py2T-LT cells and M1 and M3 clone cells for E-cadherin (E-cad) and 
vimentin. DAPI staining was used to visualize nuclei. Scale bar, 50µm. (C) Numbers 
of lung metastases per mouse transplanted orthotopically with Py2T-LT cells and M1 
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and M3 clone cells as described in (A). (D) Representative macroscopic photographs 
of lungs taken 17 days post injection of 105 Py2T-LT cells or M1 and M3 clone cells 
into the tail vein of NSG mice. Means of the numbers of metastases and the 
percentages of the metastasis area per lung tissue area per mouse were quantified. 
(E) Quantification of the incidence of lung metastasis in the mice described in C and 
D. (F) Tumor incidence assessed by transplantation of Py2T-LT cells or M1 and M3 
clone cells in limiting dilutions (1000, 100, 10 cells) into the mammary fat pads of RG 
mice. * represents the delayed tumor formation by Py2T-LT cells as compared to 
tumors initiated by M1 and M3 clone cells. The experiment was terminated 191 days 
post injection. (G) Tumor incidence of serial transplantation of fragments of tumors 
formed by M1 and M3 clone cells in the limiting dilution assay described in (F). 
Statistical significance was calculated using a Mann-Whitney U test. **, P < 0.01; ***, 
P < 0.001; ****, P < 0.0001. 
 
3.1.5.3 HDAC inhibition causes a partial MET in M 
clones 
Since the M clone cells underwent an irreversible EMT simply by manipulating 
the growth conditions, we speculated that the maintenance of their 
mesenchymal state depended on epigenetic regulators and modifications. We 
screened a number of epigenetic inhibitors to test whether any of those 
inhibitors would induce a reversion of the irreversible EMT clones to an 
epithelial state. In particular, we used 3-Deazaneplanocin A (DZNep), a 
pharmacological inhibitor of the Polycomb repressor complex component 
Ezh2 (Crea et al., 2012), a histone methyltransferase that trimethylates 
histone 3 lysine 27 (H3K27me3) and plays a key role in the initiation of an 
EMT (Tiwari et al., 2013b). We further used 5-Aza-2’-deoxycytidine (DAC) to 
inhibit DNA methylation by interfering with DNA methyltransferases (DNMTs). 
DNA methylation has been previously shown important in the reversion of an 
EMT in PC9, but not in A549 non-small-cell lung cancer cell lines (Zhang et 
al., 2017a). Finally, due to the reported roles of histone deacetylases 
(HDACs) in the reversion of an EMT in breast, ovarian, pancreatic and 
bladder carcinoma cells (Srivastava et al., 2010; Tang et al., 2016), we tested 
the HDAC inhibitor Trichostatin A (TSA) for its ability to revert mesenchymal 
M clone cells to an epithelial state.   
		 46	
Among the inhibitors tested, only TSA induced morphological changes 
towards an epithelial state in M clone cells, with a marked increase in the 
expression of the epithelial marker E-cad, yet no apparent change in the 
expression of the mesenchymal markers Fn1 and N-cad (Supplemental 
Figure S1A-D). These results indicate that histone deacetylation played a 
critical role in maintaining the mesenchymal phenotype of M clone cells. In 
contrast, treatment with DAC or DZNep did not change the mesenchymal 
phenotype of M clone cells. Bisulfite pyrosequencing of the E-cad gene 
promoter in reversible and irreversible EMT cells also did not show any 
significant change in the extent of methylated CpG islands (Supplemental 
Figure S1E), indicating that changes in DNA methylation were not 
accountable for the difference between a reversible and an irreversible EMT. 
The more specific inhibitor of Ezh2 methyltransferase activity EPZ005687 
(Knutson et al., 2012) also did not elicit any changes in cell morphology or 
EMT marker expression (Supplemental Figure S1F,G). 
Based on the effects observed with TSA and on the reported contribution of 
HDAC Class I inhibitors to the reversal of an EMT in pancreatic cancer cells 
(Meidhof et al., 2015), we treated Py2T-LT cells and M clone cells with two 
more HDAC inhibitors, the selective HDAC Class I inhibitor Tacedinaline 
(CI994) and the non-selective HDAC inhibitor Panobinostat (LBH589) 
(Beckers et al., 2007). Both inhibitors showed an efficient repression of HDAC 
activity in both M3 clone cells and Py2T-LT cells, as confirmed by 
immunoblotting analysis of H3 acetylation levels (Figure 3A). Consistent with 
a partial epithelial morphology, the inhibition of HDAC activities by CI994 and 
LBH589 provoked an increase in E-cad expression in M3 clone cells, yet 
without evident changes in N-cad and Vim expression (Figure 3A,B). Only a 
moderate loss of the mesenchymal marker Fn1 was observed in the presence 
of LBH589. Similar changes in expression patterns and cell morphology were 
observed in M1 and M2 clone cells treated with CI994 and LBH589 
(Supplemental Figure S2A,B). In comparison, despite an efficient inhibition of 
HDAC activity, Py2T-LT cells showed no obvious alterations in E-cad, Fn1, N-
cad and Vim expression upon treatment with CI994 or LBH589 (Figure 3A,B).  
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Figure 3. HDAC inhibition induces a partial MET in M clone cells (A) The protein 
levels of acetylated H3 (H3ace), fibronectin (Fn1), N-cadherin (N-cad), E-cadherin 
(E-cad), and vimentin (Vim) in M3 clones and Py2T-LT cells exposed or not to HDAC 
inhibitors (2µM Tacedinaline/CI994 or 10nM Panobinostat/LBH589) for 72 hours 
were determined by immunoblotting. Immunoblotting for total H3 and GAPDH was 
used as a loading control. (B) Morphology of M3 clone cells and Py2T-LT cells 
treated with 2µM CI994 and 10nM LBH589 for 72 hours as evaluated by phase 
contrast microscopy. Scale bar, 100µm. (C) Quantitative RT-PCR analysis of the 
mRNA levels of E-cadherin (E-cad), Claudin4 (Cldn4), fibronectin (Fn1), vimentin 
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(Vim), and Zeb1 in M3 clone cells and Py2T-LT cells treated with CI994 (2µM) and 
LBH589 (10nM) for 72 hours. Fold changes are related to mRNA levels in cells 
treated with DMSO diluent. (D) Confocal immunofluorescence microscopy analysis of 
the expression of the epithelial marker E-cadherin (E-cad) and the mesenchymal 
marker vimentin (Vim) in M3 clone cells and Py2T-LT cells in the absence and 
presence of HDAC inhibitors CI994 (2µM) and LBH589 (10nM) for 72 hours. Scale 
bar, 50µm. Data are displayed as mean ± SEM. Statistical values were calculated 
using a paired, two-tailed t-test. *, P < 0.05; **, P < 0.01, ***; P < 0.001; ****, P < 
0.0001. 
 
Quantitative RT-PCR analysis confirmed a MET in CI994 and LBH589-
treated M clone cells with increased expression of the epithelial markers E-
cad and Claudin4 (Cldn4), yet varying expression levels of the mesenchymal 
markers Fn1, Vim and Zeb1. In contrast, Py2T-LT cells remained unaffected 
by treatment with CI994 and LBH589 (Figure 3C, Supplemental Figure S2C). 
Immunofluorescence microscopy analysis revealed the specific localization of 
E-cad to cell membranes in M clone cells treated with CI994 and LBH589. In 
comparison, neither a gain of E-cad and nor a loss of Vim expression was 
observed in Py2T-LT cells treated with the HDAC inhibitors in the presence of 
TGFβ (Figure S3D, Supplemental Figure S2D).  
Together, these results indicate that M clone cells can be partially 
reverted to an epithelial state by HDAC inhibition, while Py2T-LT cells only 
revert to an epithelial phenotype by the withdrawal of TGFβ.   
 
3.1.5.4 The Mbd3/NuRD complex is critical for a 
mesenchymal state  
The fact that HDAC inhibition only partially reverted mesenchymal M clone 
cells into an epithelial state motivated us to assess whether additional factors 
were involved in the regulation of epithelial-mesenchymal plasticity. It is well 
established that multimeric protein complexes facilitate HDAC functions 
(Hayakawa and Nakayama, 2011). For example, the Mbd3/NuRD complex 
exerts its activity at least in part via HDACs and plays a critical role in the 
efficient reprogramming of MEFs into iPS cells (Rais et al., 2013).  
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To test whether the Mbd3/NuRD complex was a critical component in 
the maintenance of a mesenchymal state, we ablated Mbd3 expression in M 
clone cells by the stable expression of shRNAs targeting Mbd3. Indeed, the 
efficient depletion of Mbd3 led to an epithelial morphology of M clone cells 
with increased expression of E-cad and Cldn4, accompanied by reduced 
expression of Vim, Fn1, N-cad and Zeb1 at both the protein and mRNA level, 
compared to shControl-transfected cells (Figure 4A,B). In contrast, the 
efficient depletion of Mbd3 in Py2T-LT cells failed to affect the expression of 
EMT markers (Figure 4A,B). SiRNA-mediated depletion of Mbd3 elicited 
similar changes in EMT marker expression, yet at lower efficiency 
(Supplemental Figure S3A,B). In contrast, shRNA-mediated depletion of 
Mbd3 in Py2T-LT cells rather led to increased E-cad mRNA levels and no 
change in Cldn4, Fn1, Vim and Zeb1 expression  (Figure 4C). 
Confocal immunofluorescence microscopy analysis indicated that 
shRNA and siRNA-mediated ablation of Mbd3 in M3 clone cells led to a 
localization of the epithelial marker proteins E-cad and ZO-1 to cell-cell 
junctions, to the conversion of mesenchymal stress fibers to epithelial cortical 
actin and to a reduction in Vim expression, compared to cells transfected with 
shControl (Figure 4D, Supplemental Figure S3C). In contrast, depletion of 
Mbd3 in Py2T-LT cells failed to induce a membrane localization of E-cad and 
ZO-1 and did not affect actin stress fibers or the expression of Vim (Figure 
4D, Supplemental Figure S3C). Together, these results indicate that Mbd3 
plays a critical role in sustaining the mesenchymal state of M clone cells. 
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Figure 4. The Mbd3/NuRD complex is required for the maintenance of a 
mesenchymal cell state (A) The protein levels of fibronectin (Fn1), N-cadherin (N-
cad), E-cadherin (E-cad), vimentin (Vim), and Mbd3 were evaluated by 
immunoblotting in M3 clone cells and in Py2T-LT cells expressing either shControl or 
shMbd3. Immunoblotting for GAPDH was used as a loading control. (B) Phase-
contrast microscopy of M3 clone cells and Py2T-LT cells stably expressing shControl 
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or shMbd3. Scale bar, 100µm. (C) Quantitative RT-PCR analysis of the mRNA levels 
of Mbd3, E-cadherin (E-cad), Claudin4 (Cldn4), fibronectin (Fn1), vimentin (Vim), and 
Zeb1 in M3 clone cells and Py2T-LT cells expressing shMbd3. Fold changes are 
related to M3 clone cells and Py2T-LT cells expressing shControl. (D) Confocal 
immunofluorescence microscopy analysis of the expression and localization of the 
epithelial markers E-cadherin (E-cad) and ZO-1 and the mesenchymal marker 
vimentin (Vim) in M3 clone cells and Py2T-LT cells expressing either shControl or 
shMbd3. Phalloidin and DAPI staining visualize the actin cytoskeleton and nuclei, 
respectively. Scale bar, 50µm. Data are displayed as mean ± SEM. Statistical values 
were calculated using a paired, two-tailed t-test. *, P < 0.05; **, P < 0.01. 
 
We next compared the genes differentially expressed between 
shControl and shMbd3-expressing M3 clone cells to the differentially 
expressed genes between Py2T-LT and M3 clone cells by RNA sequencing. 
1351 genes were found to be specific for the Mbd3-dependent stable 
mesenchymal state (Supplemental Figure S3D). The majority of these genes 
(940 out of 1351) were differentially regulated by the depletion of Mbd3 
(Supplemental Figure S3E), indicating that Mbd3 affects a wide range of 
genes to maintain the mesenchymal state of M clone cells. 
 
3.1.5.5 Tet2 is required for the maintenance of the 
mesenchymal cell state 
Based on reports that 5hmC was critical for the recruitment of the 
Mbd3/NuRD complex to its target genes in embryonic stem cells (ESCs) 
(Yildirim et al., 2011), we assessed whether Tet family hydroxylases played a 
role in maintaining the mesenchymal phenotype of M clone cells. Of the three 
family members, only the shRNA-mediated knock-down of Tet2 expression in 
M3 clone cells provoked a conversion to an epithelial cell morphology, an 
evident elevation of E-cad and Cldn4 expression and a reduced expression of 
Vim, Fn1, N-cad and Zeb1 at both the protein and mRNA level (Figure 5A-C). 
In contrast, knockdown of Tet2 expression in Py2T-LT cells did not affect cell 
morphology or EMT marker expression (Figure 5A-C).  
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Figure 5. Tet2 is required for the maintenance of a mesenchymal cell state (A) 
Protein levels of Tet2, fibronectin (Fn1), N-cadherin (N-cad), E-cadherin (E-cad), and 
vimentin (Vim) were determined by immunoblotting in M3 clone cells and Py2T-LT 
cells expressing either shControl or shTet2. Immunoblotting for GAPDH was used as 
a loading control. * indicates a non-specific protein band stained by anti-Tet2 
antibodies. (B) Phase-contrast microscopy of M3 clone cells and Py2T-LT cells 
expressing shControl or shTet2. Scale bar, 100µm. (C) Quantitative RT-PCR 
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analysis of the mRNA levels of Tet2, E-cadherin (E-cad), Claudin4 (Cldn4), 
fibronectin (Fn1), vimentin (Vim), and Zeb1 mRNA levels in M3 clone cells and Py2T-
LT cells expressing shTet2. Fold changes are related to cells expressing shControl. 
(D) Confocal immunofluorescence microscopy analysis of the expression and 
localization of E-cadherin (E-cad) and ZO-1 and vimentin (Vim) in M3 clone cells and 
Py2T-LT cells expressing either shControl or shTet2. Phalloidin and DAPI staining 
visualize the actin cytoskeleton and nuclei, respectively. Scale bar, 50µm. Data are 
displayed as mean ± SEM. Statistical values were calculated using a paired, two-
tailed t-test. *, P < 0.05; **, P < 0.01, ***; P < 0.001. 
 
Comparable results were obtained with siRNA-mediated ablation of 
Tet2 expression in M3 clone cells and in Py2T-LT cells (Supplemental Figure 
S4A,B). 
Confocal immunofluorescence microscopy analysis revealed the 
localization of E-cad and ZO-1 at cell-cell junctions, accompanied by cortical 
actin formation and reduced Vim expression in shTet2-expressing M3 clone 
cells (Figure 5D). In comparison, shRNA-mediated depletion of Tet2 in Py2T-
LT cells did not show any effect (Figure 5D). The transient ablation of Tet2 
expression by transfection of siRNAs confirmed these results (Figure S4C). 
Together, the results indicate that Tet2 is a critical player in the maintenance 
of a mesenchymal state in irreversible EMT cells. 
Next generation RNA-sequencing revealed that 1116 were shared 
between the genes changed in their expression by depletion of Tet2 in M3 
clone cells and genes differentially expressed between M3 clone cells and 
Py2T-LT cells (Supplemental Figure S4D). Similar to the depletion of Mbd3, 
the majority of these genes (760 out of 1116) were differentially regulated by 
the loss of Tet2 expression (Supplemental Figure S4E), indicating a profound 
function of Tet2 and Mbd3 in maintaining a mesenchymal cell state. 
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3.1.5.6 Combinatorial targeting of HDACs and 
Mbd3/Tet2 
The above results indicate that the pharmacological inhibition of HDACs alone 
induces only a partial reversion of mesenchymal M clone cells to an epithelial 
state. By contrast, interfering with the Mbd3/NuRD complex, which may also 
involve HDAC and Tet2 activities, leads to an efficient reversion of M clone 
cells to an epithelial phenotype. Hence, we tested whether a combination of 
pharmacological HDAC inhibition with the ablation of Mbd3 or Tet2 provided 
an additive effect in reverting M clone cells to an epithelial state. M3 clone and 
Py2T-LT cells expressing shControl, shTet2 or shMbd3 were treated with 
CI994 or with solvent control. While the specific shRNAs efficiently depleted 
Mbd3 and Tet2 expression, respectively, CI994 efficiently inhibited HDAC 
enzymatic activity (Figure 6A). Interestingly, the ablation of both Tet2 and 
Mbd3 caused an apparent upregulation of H3 acetylation levels even in the 
absence of CI994, indicating the depletion of Tet2 and Mbd3 also affected 
HDAC activity (Figure 6A), likely by disrupting Mbd3/NuRD complexes. In 
combination with CI994 treatment, Tet2 and Mbd3-depleted M3 clone cells 
showed an increased expression of E-cad accompanied by the loss of Vim 
and Fn1 expression, as compared to the depletion of either Mbd3 or Tet2 
alone or treatment with CI994 alone (Figure 6A). All treated cells showed an 
epithelial cell morphology which did not markedly increase upon combination 
treatment (Figure 6B). Notably, the combined ablation of Tet2 or Mbd3 with 
CI994 treatment also induced an increase in E-cad expression and reduced 
Fn1 and N-cad expression in Py2T-LT cells, in addition with a less elongated 
cellular phenotype (Figure 6B). The increased efficiency of a MET in M clone 
cells and Py2T-LT cells upon combinatorial treatment was also apparent by 
quantitative RT-PCR analysis of EMT marker expression (Supplemental 
Figure S5A). 
 
			
		 55	
 
 
Figure 6. Combination of the depletion of Mbd3 or Tet2 expression with HDAC 
inhibition potentiates an MET of stable mesenchymal cells (A) Protein levels of 
Tet2, fibronectin (Fn1), N-cadherin (N-cad), E-cadherin (E-cad), vimentin (Vim) and 
Mbd3, as determined by immunoblotting of M3 clone cells and Py2T-LT cells stably 
expressing shControl, shTet2 or shMbd3 and cultured in the absence or presence of 
2µM CI994 for 72 hours. Immunoblotting for GAPDH was used as a loading control. * 
indicates a non-specific protein band bound by anti-Tet2 antibodies. (B) Phase-
contrast microscopy of M3 clones cells and Py2T-LT cells expressing shControl, 
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shTet2 or shMbd3 and cultured in the absence or presence of 2µM CI994. Scale bar, 
100µm. (C) Confocal immunofluorescence microscopy analysis of the localization 
and expression of ZO-1 and vimentin (Vim) in M3 clone cells and Py2T-LT cells 
expressing shControl, shTet2 or shMbd3 and cultured in the absence or presence of 
2µM CI994 for 72 hours. Phalloidin and DAPI staining visualize the actin cytoskeleton 
and nuclei, respectively. Scale bar, 50µm. 
 
Immunofluorescence microscopy analysis confirmed these results. The 
depletion of Tet2 and Mbd3 in M3 clone cells in combination with CI994 
treatment induced a more efficient localization of E-cad and ZO-1 at cell-cell 
junctions and the formation of cortical actin while enhancing a reduction in 
Vim expression, as compared to the ablation of either Mbd3 or Tet2 and 
CI994 treatment alone (Figure 6C, Supplemental Figure S5B). In contrast, the 
combinatorial treatment of Py2T-LT cells did neither provoke the localization 
of E-cad and ZO-1 at cell-cell junctions nor reduce mesenchymal Vim 
expression and actin stress fiber formation. Overall, these results underscore 
the observation that the combined inhibition of HDACs and the ablation of 
Mbd3 or Tet2 provides an additive effect in converting otherwise irreversible 
EMT cells to an epithelial state. The results also suggest that a functional 
Mbd3/NuRD complex together with HDAC and Tet2 hydroxylase activities is 
required for the maintenance of the mesenchymal cell state. 
We further went on to identify the genes that are critical for the 
maintenance of the mesenchymal cell state in M clone cells. We first identified 
367 genes that are differentially expressed upon treatment of M3 clone cells 
with the HDAC inhibitor CI994 or by the depletion of Mbd3 or Tet2 alone 
(Supplemental Figure S6A). We also identified 784 genes that are 
differentially regulated between Mbd3 or Tet2 depletion alone and Mbd3 or 
Tet2 depletion in combination with CI994 treatment (Figure S6A). Finally, we 
compared the 367 genes shared between CI994, shMbd3 and shTet2 
treatments and the 784 genes that are assigned to the additive effect of 
HDAC inhibition in combination with Mbd3 and Tet2 depletion. This 
comparison identified 92 genes which change in their expression by all the 
treatments leading to an MET of M clone cells. We hypothesize that the 92 
genes could be responsible for the additive effect of HDAC inhibition and 
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Mbd3 or Tet2 depletion during an MET of M clone cells and we refer to this list 
of genes as “induced MET (iMET)” gene signature (Figure S6A; Supplemental 
Table S1).  
We next assessed whether the iMET genes were also differentially 
regulated during an MET of a reversible EMT system. RNA-sequencing was 
performed at early, middle and late time points of a MET of Py2T-LT cells 
upon TGFβ withdrawal (Py2T MET; Supplemental Table S1). Differentially 
expressed genes during the time course of Py2T MET cells were then 
compared to the 92-gene iMET signature (Supplemental Figure S6B). This 
analysis revealed not only common but also distinct gene expression patterns 
between the iMET gene signature and the genes changing during the 
reversible MET time course. The results further highlight the notion that, while 
sharing some regulatory pathways, an irreversible and a reversible EMT are 
distinct processes. 
 
3.1.5.7 Tet2 and Mbd3 are required for primary tumor 
growth and metastasis  
The critical role of Tet2 and the Mbd3/NuRD complex in an MET of M clone 
cells in vitro raised the question whether these epigenetic modifiers also play 
a role during metastasis formation in vivo. To address this question, M3 clone 
cells stably expressing shRNAs against Tet2 (shTet2), Mbd3 (shMbd3) and a 
non-targeting control-shRNA (shControl) were orthotopically implanted into 
the mammary fat pads of NSG mice. When the tumors were first palpable, 
daily treatment with CI994 was initiated (35 mg/kg; i.p.). The ablation of Tet2 
and Mbd3 led to a significant decrease in primary tumor growth and tumor 
weights. The combination with CI994 treatment caused a further significant 
reduction in tumor growth and tumor weights as compared to the vehicle-
treated cohorts (Figure 7A,B). The efficient depletion of Tet2 and Mbd3 
expression and the efficacy of CI994-mediated inhibition of HDAC activity in 
the tumors were verified by immunoblotting (Figure 7C). Quantitative RT-PCR 
revealed that the combinatorial treatment with CI994 enhanced the 
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upregulation of epithelial markers and the downregulation of mesenchymal 
markers in Tet2 and Mbd3-depleted primary tumors (Figure 7D).  
 
 
 
Figure 7. Depletion of Mbd3 or Tet2 expression in combination with HDAC 
inhibition efficiently represses primary tumor growth and lung metastasis (A) 
105 shControl, shTet2, and shMbd3-expressing M3 clone cells were transplanted into 
the mammary fat pad of female NSG mice. When the tumors were palpable, mice 
were treated with HDAC inhibitor CI994 (35 mg/kg, i.p.), and tumor growth was 
measured over time. At least 5 mice were used for experimental cohort. Data are 
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displayed as mean tumor volumes ± SEM. (B) The mice described in (A) were 
sacrificed after 29 days of treatment and tumor weights were assessed. (C) The 
expression of Tet2 (left panel), Mbd3 (right panel), and acetylated H3 (H3 acetyl) in 
tumors of the mice described in (A and B) was analyzed by immunoblotting. 
Immunoblotting for GAPDH and total H3 was used as loading control. (D) 
Quantitative RT-PCR analysis of the mRNA levels of Tet2 and Mbd3 (left panel) and 
E-cadherin (E-cad), Claudin4 (Cldn4), fibronectin (Fn1) and vimentin (Vim) (right 
panel) in shTet2 or shMbd3 expressing tumors from mice described in (A and B). 
Fold changes relate to mRNA levels in tumors expressing shControl and treated with 
vehicle control. (E) Metastatic spread of shControl, shTet2 and shMbd3-expressing 
M3 clone tumors treated with vehicle or HDAC inhibitor CI994 was determined by 
serial sectioning of the lungs of mice described in (A and B). The metastatic index 
was calculated by the number of metastases divided by the primary tumor weights 
within the same mice (left panel). Mean of the number of metastases (middle panel) 
and metastatic area percentages per mouse were also quantified (right panel). 
Statistical significance was calculated using a Mann-Whitney U test. N.s., non-
significant; *, P< 0.05; **, P < 0.01. 
 
The ablation of Tet2 and Mbd3 also significantly reduced the number 
and the tissue area of metastasis in the lungs of transplanted mice, even 
when the number of metastases was normalized to the decreased primary 
tumor weights observed with the depletion of Tet2 or Mbd3 (metastatic index; 
Figure 7E). Remarkably, no metastatic lesions could be detected in mice 
implanted with shMbd3-expressing M3 clone cells with or without CI994 
treatment. Notably, the inhibition of HDACs by itself did not cause a significant 
reduction in the number of lung metastasis, their surface area or metastatic 
index. 
Altogether, these findings indicate that Tet2 and the Mbd3/NuRD 
complex play a pivotal role during primary tumor growth and metastasis 
formation. While a combinatorial treatment with HDAC inhibitors and the 
genetic depletion of Mbd3 or Tet2 shows an additive effect on MET of murine 
breast cancer cells in vitro and primary tumor growth in vivo, this additive 
effect is not apparent in the inhibition of tumor metastasis formation in vivo.  
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3.1.6 Discussion 	
We have set out to identify molecular pathways and mechanisms underlying 
the reversibility and irreversibility of an EMT in murine breast cancer cells. 
These pathways may serve as potential therapeutic targets to interfere with 
the metastatic dissemination and outgrowth of malignant cancer cells. 
Towards this goal, we have used Py2T murine breast cancer cells that 
undergo a reversible EMT upon stimulation with TGFβ to generate derivatives 
that maintain a stable mesenchymal phenotype upon normal culture 
conditions (M clones). We find that M clone cells can be forced to undergo an 
MET when treated with HDAC inhibitors or when depleted of Mbd3 or Tet2 
expression. Notably, these pharmacological or genetic interferences, 
individually or in combination, efficiently repressed primary tumor growth and 
metastasis formation of highly tumorigenic and metastatic M clone cells. The 
results indicate that the Mbd3/NuRD complex containing HDACs and Tet2 
may play a critical role in defining the epithelial-mesenchymal plasticity during 
an EMT and a MET and during the metastatic process. Combinatorial 
targeting of its components may thus offer an efficient approach to interfere 
with malignant disease. 
Previous studies have mainly focused on HDACs’ functional 
contributions to cancer cell apoptosis, proliferation and angiogenesis. The role 
of HDACs in epithelial-mesenchymal plasticity has remained unclear. Some 
reports show that HDAC inhibition induces an EMT in prostate, 
nasopharyngeal, colon and liver carcinoma cells (Kong et al., 2012); (Jiang et 
al., 2013). In contrast, other reports indicate that HDAC inhibition results in a 
partial MET state in breast, ovarian, bladder and pancreatic cancer cells 
(Tang et al., 2016; Tate et al., 2012). Finally, HDAC inhibition represses drug 
resistance of cancer cells forced to undergo an EMT by the expression of the 
transcription factor Zeb1 (Meidhof et al., 2015). Our results are consistent with 
the latter reports in that HDAC inhibition causes a partial MET phenotype in 
irreversible EMT cells, whereas no marked effects are observed in reversible 
EMT cells. In addition, we show that HDAC inhibition represses primary tumor 
growth with a significant upregulation of epithelial marker expression, yet with 
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no marked decrease in mesenchymal marker expression. Surprisingly, HDAC 
inhibition alone had no discernable effect on lung metastasis. Conflicting with 
our results, it has been reported that HDAC inhibition represses metastasis of 
hepatocellular carcinoma cells (Coradini et al., 2004).  
A critical role for the HDAC1/2-containing Mi-2/NuRD complex during 
an EMT has been previously reported: it is recruited for the silencing of the E-
cadherin (Cdh1) gene promoter by the EMT transcription factors Snail and 
Twist (Fujita et al., 2003); (Fu et al., 2011). The role of the Mbd3/NuRD 
complex as another type of NuRD complex during an EMT or a MET has 
remained elusive. Yet, the HDAC1/2- containing Mbd3/NuRD complex has 
been shown to act as a molecular block during ES cell differentiation and 
reprogramming of MEFs into iPS cells (Rais et al., 2013). We here report that 
Mbd3 is critical for the maintenance of a mesenchymal cell state and that its 
depletion results in a conversion to an epithelial cell phenotype. Moreover, the 
depletion of Mbd3 dramatically reduces primary tumor growth and completely 
abolishes the formation of metastasis.  
Mbd3 interacts with Tet1 and regulate its target genes by recognizing 
5hmC-rich DNA domains (Yildirim et al., 2011). On the other hand, it has been 
suggested that Mbd3 binding to DNA is independent of the presence of 5hmC 
and 5mC sites, even though Mbd3/NuRD co-exists with Tet1 and 5hmC 
positive sites (Baubec et al., 2013). Notably, DNA demethylation mediated by 
Tet hydroxylases and Tdg is required for a MET and the reprogramming of 
MEFs into iPS cells (Hu et al., 2014). In contrast, we here find that the 
ablation of Tet2 leads to a reversion of cells from a stable mesenchymal to an 
epithelial state. It has been recently reported that Tet2 could be de-acetylated 
by interacting with HDAC1 and HDAC2 and that interfering with their activities 
results into the repression of Tet2 activity and an increase in global 5hmC 
levels (Zhang et al., 2017b). Our results show that the inhibition of HDAC 
class I in combination with the depletion of Tet2 provides an additive effect to 
the reversion of mesenchymal M3 clone cells to an epithelial state.  
Here, we demonstrate an important regulatory role of the epigenetic 
modifiers Mbd3/NuRD and Tet2 in the regulation of cell state transitions and 
of primary tumor growth and metastasis by their ability to affect the expression 
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of a wide range of genes. Notably, we have identified a 92 gene iMET 
signature representing genes that are differentially regulated during an MET 
of irreversible EMT cells induced by a combination of HDAC inhibition and 
depletion of Mbd3 and/or Tet2. Most importantly, our work identifies the 
inhibition of HDACs and of Tet2 and the Mbd3/NuRD complex as suitable 
therapeutic targets to interfere with primary tumor growth and metastasis 
formation. While potent pharmacological inhibitors against HDACs have been 
developed and are in clinical trials, their clinical efficacy appears sobering. 
Our work suggests that HDAC inhibition should be combined with the 
inhibition of Mbd3/NuRD and Tet hydroxylases. Unfortunately, efficient 
inhibitors of Tet hydroxylases and of the Mbd3/NuRD complex are only in 
development or are lacking (Scourzic et al., 2015). It has been reported that 
2-hydroxyglutarate (2-HG) could inhibit Tet enzymes (Xu et al., 2011). 
However, many other α-ketoglutarate-dependent dioxygenases may be 
targeted as well (Xiao et al., 2012). Hence, specific inhibitors for Tet enzymes 
need to be developed to test their efficacy in repressing primary tumor growth 
and metastasis formation alone and in combination with HDAC inhibitors. Due 
to their pleiotropic mode of action and their reversible nature, these epigenetic 
modifiers are attractive targets for the development of novel cancer therapies. 
 
3.1.7 Material and Methods 
Reagents and antibodies 
Reagents: recombinant human (rh) TGFβ1 (240-B, R&D Systems), DMEM 
(D5671, Sigma-Aldrich), MEGM (C-21010, PromoCell) with SupplementMix 
(C-39115, PromoCell), PBS (D8537, Sigma-Aldrich), trypsin (T4174, Sigma-
Aldrich), FBS (F7524, Sigma-Aldrich), glutamine (G7513, Sigma-Aldrich), 
pencillin/streptomycin (P4333, Sigma-Aldrich), Opti-MEM (11058-021, Gibco), 
Lipofectamine RNAiMax (13778-150, Invitrogen), Alexa Fluor-488, 568, 633 
(Invitrogen), Polybrene (107689, Sigma-Aldrich), Puromycin (ant-pr-5b, 
Invivogen), JetPEI (101-10, Polyplus), TRI Reagent®  (T9424, Sigma-
Aldrich), M-MLV reverse transcriptase (M314C, Promega), PowerUP™ 
SYBR® green Master Mix (A25743, ThermoFisher), Bradford reagent (500-
0006, Biorad), protease inhibitor cocktail (P2714, Sigma-Aldrich). 
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Antibodies for immunoblotting: E-cadherin (610182, Transduction 
Laboratories), N-cadherin (M142, Takara), Fibronectin (F-3648, Sigma-
Aldrich), GAPDH (ab9485, Abcam), Vimentin (5741, Cell Signaling), Mbd3 
(14540, Cell Signaling), Tet2 (ab124297, Abcam), H3 acetyl (06-599, 
Millipore), H3K27me3 (07-449, Millipore), Histone H3 (ab1791, Abcam). 
Antibodies for immunofluorescence: E-cadherin (13-1900, Zymed), Vimentin 
(V225, Sigma-Aldrich), Vimentin (NB300-223, Novus Biological, used in 
tissues), ZO-1 (617300, Zymed), Phalloidin (A12380, Invitrogen), N-Cadherin 
(610921, Transduction Laboratories). 
siRNAs: siControl (ON-TARGET plus Non-Targeting pool, D-001810-10, 
Dharmacon), siTet2 (M-058965-01, Dharmacon), siMbd3 (M-047318-01, 
Dharmacon). 
shRNAs: shControl (Mission Non-target shRNA control vector, SHC002), 
shTet2 (SHCLNG- NM_145989 Mouse, TRCN0000201087), shMbd3 
(SHCLNG- NM_013595 Mouse, TRCN0000304501). 
Pharmacological inhibitors: LBH589 (Panobinostat, S1030, Selleckchem), 
CI994 (Tacedinaline, S2818, Selleckchem, used for in vitro studies), CI994 
(Tacedinaline, A4102, Apexbio, used for in vivo studies), Trichostatin A (TSA, 
T8552, Sigma-Aldrich), 3-Deazaneplanocin A (DZNep, 13828, Cayman 
Chemical), EPZ005687 (S7004, Selleckchem), 5-Aza-2’-deoxycytidine 
(Decitabine, A3656, Sigma-Aldrich). 
 
Cell lines 
Py2T cells (Waldmeier et al., 2012) and M clone cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with glutamine, 
penicillin, streptomycin and 10% FBS (Sigma-Aldrich). Py2T cells were 
treated with 2ng/ml TGFβ1 and the medium was replenished every 3 days. All 
cells were cultured at 37°C with 5% CO2 in a humid incubator. 
In vitro irreversible EMT clones: M clones were generated by culturing in 
MEGM supplemented with SupplementMix (PromoCell) and glutamine, 
penicillin, streptomycin and 7% FBS (Sigma-Aldrich) for 3 months, when 
subpopulations of mesenchymal cells became apparent. Then, cells were 
transferred into DMEM supplemented with glutamine, penicillin, streptomycin 
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and 10% FBS (Sigma-Aldrich) and cultured for 2 months to select for stable 
mesenchymal subpopulations which were subsequently isolated as single 
cells and expanded as cell clones in 96-well plates. 
Inhibitor treatments: Py2T-LT cells and M clone cells were treated with 2µM 
CI994 or 10nM LBH589 for 3 days. M2 and M3 clones were treated with 5µM 
DZNep, 2µM Decitabine, or 100nM TSA for 3 days. Py2T-LT cells and M3 
clones were treated with 5µM CI994 or 5µM EPZ005687 for 6 days. 
RNA isolation and quantitative RT-PCR 
Total RNA was prepared using TRI Reagent (Sigma-Aldrich) for cultured cells 
or RNeasy mini kit (74104, Qiagen) for tissues and for RNA sequencing by 
using miRNeasy mini kit (217004, Qiagen). RNA was reverse transcribed with 
M-MLV reverse transcriptase (Promega), and transcripts were quantified by 
PCR using PowerUP SYBR green Master Mix (Thermo Fisher Scientific) in a 
StepOne Plus PCR machine (Applied Biosystems). Ribosomal protein L19 
expression (RPL19) primers were used for normalization and fold changes 
were calculated using the comparative Ct method (ΔΔCt). Primers used for 
quantitative RT-PCR are listed in Supplemental Table S2.  
 
Immunofluorescence staining of cultured cells 
Cells were plated on glass coverslips, fixed with 4% paraformaldehyde/ PBS 
for 20 min and permeabilized with 0.5% NP-40 for 10 min at room 
temperature. Next, cells were rinsed and blocked using 3% BSA, 0.01% Triton 
X- 100 in PBS for 30 min at room temperature. Subsequently, cells were 
incubated with primary antibodies against E-cadherin, N-cadherin, ZO-1, 
Vimentin overnight at 4ºC. Cells were rinsed 3 times with blocking reagent 
followed by incubation with fluorochrome-labeled secondary antibodies or 
phalloidin-568 (Invitrogen) for 1 hour at room temperature. The coverslips 
were counterstained with DAPI (Sigma-Aldrich) for 5 min, rinsed 3 times, 
mounted (Fluorescent mounting medium, Dako) on microscope slides and 
imaged with a conventional immunofluorescence microscope (Leica DMI 
4000) or a confocal laser scanning microscope (Leica SP5). Data were 
processed with Fiji Sofware. 
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Immunoblotting 
Cells were lysed in RIPA buffer (150mM NaCl, 2mM MgCl2, 2mM CaCl2, 0.5% 
NaDOC, 1% NP40, 0.1% SDS, 10% Glycerol, 50mM Tris pH 8.0) containing 
2mM Na3VO4, 10mM NaF, 1mM DTT, and a 1:200 dilution of stock protease 
inhibitor cocktail for mammalian cells (Roche). Protein concentration was 
determined using the Bradford assay (Bio-Rad). Equal amounts of protein 
were diluted in SDS-PAGE loading buffer (10% glycerol, 2% SDS, 65mM Tris, 
1mg/100 ml bromophenol blue, 1% β-mercaptoethanol) and resolved by SDS-
PAGE. Proteins were transferred to polyvinylidene fluoride (PVDF) 
membranes (Millipore) by wet transfer, blocked with 5% skim milk powder in 
TBS/0.05% Tween 20 and incubated with the indicated antibodies. HRP-
conjugated secondary antibodies were detected by chemiluminescence with 
X-ray films (FUJIFILM).  
 
Histone extraction 
Cells were resuspended in lysis buffer (10mM HEPES, pH 7.9, 1.5mM MgCl2, 
10mM KCl, 0.5mM DTT) containing 1:200 dilution of protease inhibitor cocktail 
for mammalian cells (Roche). Acid extraction of histones from the nuclei was 
achieved by HCl to the final concentration of 0.2M and incubated for 30 min. 
Subsequently, the samples were centrifuged for 10 min and supernatant was 
neutralized with 5M NaOH. 
 
Pyrosequencing of bisulfite-converted DNA 
Genomic DNA was isolated from 106-107 cells by collection in 300µl Tris-
EDTA buffer (10mM Tris-HCl pH 8.0, 1mM EDTA). Then, 300µl lysis buffer 
(20mM Tris-HCl pH 7.5, 4mM EDTA, 20mM NaCl, 1% SDS, 1mg/ml 
proteinase K) were added and incubated at 50°C for 5h. Subsequently, DNA 
was extracted by phenol/chloroform and precipitated by Na-acetate/ethanol. 
DNA pellets were resuspended in Tris-EDTA buffer pH 8.0, followed by 
RNase A (R6513, Sigma-Aldrich) at 37°C for 30min. Genomic DNA was 
treated with sodium bisulfite using the Epitect Bisulfite Kit (59104, Qiagen) 
according to the manufacturer ́s instructions.  
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The bisulfite converted E-cadherin (E-cad) gene promoter region was PCR 
amplified by using methylation-specific primers with the biotin-labeled reverse 
primers at the 5’-end and HPLC-purified by using unconverted DNA as a 
negative control. PCR reactions were performed with 0.05 units JumpStart 
Taq DNA Polymerase (D4184, Sigma-Aldrich) per µl reaction volume 0.4µM 
primers and 2.5mM MgCl2 in 50µl reactions. After 5 min of initial denaturation 
at 95°C, the cycling conditions of 35 cycles consisted of denaturation at 95°C 
for 30 s, annealing at 58°C for 30 s and elongation at 72°C for 2 min. Then, 
PCR products loaded on the gel and purified by using GenElute PCR Clean-
up kit (NA1020, Sigma-Aldrich). 500ng of biotin-labeled PCR products were 
immobilized on streptavidin-coated sepharose beads (GE Healthcare) and 
sequenced with a PyroMark Q24 pyrosequencing system (Qiagen) according 
to the manufacturer ́s instructions (adapted from (Noreen et al., 2014). The 
sequences of PCR and sequencing primers are given in Supplemental Table 
S3. 
 
RNA-sequencing and data analysis:  
Total RNA was isolated from cells of 2 independent experiments using the 
miRNeasy Mini Kit (Qiagen) according to the manufacturer’s instruction. RNA 
quality control was performed with a fragment analyzer using the standard or 
high sensitivity RNA analysis kit (DNF-471-0500 or DNF-472-0500) from 
Labgene and RNA concentration was measured by using the Quanti-iTTM 
RiboGreen RNA assay kit (Life Technologies/Thermo Fisher Scientific). 200ng 
of RNA was utilized for library preparation with the TruSeq Stranded Total 
RNA LT Sample Prep Kit (Illumina). RNA-sequencing was carried out in the 
Genomics Facility (Basel) by HiSeq SBS kit v4 (Illumina) on an Illumina HiSeq 
2500 and by NextSeq 500/550 High Output kit v2 (Illumina) on an Illumina 
NextSeq 500 according to manufacturer’s instructions. 
Obtained single-end RNA-seq reads were mapped to the mouse genome 
assembly, version mm10, with RNA-STAR (Dobin et al., 2013), with default 
parameters except for allowing only unique hits to genome 
(outFilterMultimapNmax=10) and filtering reads without evidence in spliced 
junction table (outFilterType="BySJout"). Using RefSeq mRNA coordinates 
from UCSC (genome.ucsc.edu, downloaded in December 2015) and the 
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qCount function from QuasR package (version 3.12.1) (Gaidatzis et al., 2015), 
we quantified gene expression as the number of reads that started within any 
annotated exon of a gene. The differentially expressed genes were identified 
using the edgeR package (version 1.10.1) (Robinson et al., 2010). Genes with 
p-value smaller than 0.05 and minimum log2 fold change of +/-0.584 were 
used for downstream analysis. 
Batch effect correction and correlation analysis: Correlation analysis between 
MET, M3 clone (with CI994 inhibitor), depletion of Mbd3, Tet2 in M3 clone 
(with and without inhibitor) was performed on CPM (counts per million) data 
after correcting the batch effect using ComBat (Johnson et al., 2007). 
Correlation was computed using the Pearson method, and linkage criteria 
used was average. Hierarchical clustering was performed using “hclust” and 
heatmaps were generated using the heatmap2 function. 
 
Lentiviral infection 
Lentiviral plasmids containing short-hairpin RNAs (shRNA) against murine 
Tet2 and Mbd3 and the Non-Targeting shRNA control vector were purchased 
from Sigma. In order to produce lentiviral particles, HEK293T cells were 
transfected with the shRNA-encoding plasmids, the helper vectors pMDL and 
pREV and the envelope-encoding plasmid pVSV by JetPEI (Polyplus). Virus-
containing supernatant was conditioned for 2 days. Viral supernatant was 
harvested and filtered (0.46µm), supplemented with polybrene (8ng/ml) and 
used to infect M3 clone cells and Py2T-LT cells. Infected cells were selected 
with 2µg/ml puromycin (Invitrogen).  
 
siRNA-mediated knockdown 
For a transient knockdown of Tet2 and Mbd3, 30nM and 40nM final 
concentrations of siGENOME smart pool siRNAs (Dharmacon) were used for 
M clone cells and Py2T-LT cells, respectively. A non-targeting pool was used 
as a negative control (Dharmacon). Reverse and forward transfections of 
siRNAs were performed with Lipofectamine RNAiMax reagent (Invitrogen) 
according to the manufacturer’s instructions.  
 
		 68	
Tumor transplantations 
Mammary fat pad injection: 14-17 weeks old female NOD_scid_gamma (NSG 
mice; a kind gift from Nicola Aceto, University of Basel, Basel, Switzerland) 
were anaesthetized with isoflurane/oxygen and injected with 1x105 Py2T-LT 
cells, M1 and M3 clones in 100µl PBS into mammary gland number 9. 10 
mice were used per experimental cohort. Tumors were measured by digital 
caliper, and tumor volumes were calculated according to the formula V = 
0.543 x l x w2, where l represents length and w represents width of tumors 
measured by a digital caliper. When the tumors reached a maximal volume of 
1 cm3, mice were sacrificed by using CO2, and tumors were isolated and 
further processed for further analysis.  
CI994 treatment: 105 M3 cells (shControl, shTet2 and shMbd3) were 
orthotopically injected into the mammary fat pads of NSG mice as described 
above. 5-6 mice were used per treatment cohort. Once tumors were palpable, 
mice were treated daily with vehicle alone (5% DMSO, 30% Kolliphor, 65% 
Saline water) or with 35mg/kg CI994 (Tacedinaline, Apexbio) by i.p. injection. 
Mice were sacrificed 29 days post injection for shControl and shTet2, CI994 
and vehicle-treated groups and 33 days for shMbd3, CI994 and vehicle-
treated groups, due to the 4 days difference of the treatment start date. 
Intra-venous injection: Py2T-LT cells, M1 and M3 clones were injected at a 
final concentration of 105 in 100µl PBS into the tail veins of 14-17 weeks old 
female NSG mice. Mice were sacrificed after 17 days, and lung metastasis 
was quantified by H&E staining of histological sections. 
Tumor tissue transplantation: BALB/c Rag2−/−;common γ receptor−/− (RG 
mice; a kind gift from A. Rolink, University of Basel, Basel, Switzerland) were 
transplanted with 1-2 mm3  of M1 and M3 clones derived tumor into the 
mammary fat pads of 3 mice. Mice were sacrificed, when the tumors reached 
a maximal volume of 1 cm3. Transplantation experiments were repeated for 2 
generations. All experiments were performed following the rules and 
legislations of the Cantonal Veterinary Office and the Swiss Federal 
Veterinary Office (SFVO). 
 
Haematoxylin & Eosin staining 
For Haematoxylin & Eosin (H&E) staining, lungs were fixed at 4°C in 4% 
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phosphate buffered paraformaldehyde (PFA) for 12 hours and then 
embedded in paraffin after ethanol/xylene dehydration. H&E staining was 
performed as previously described (Wicki et al., 2006). Staining and 
metastasis number were evaluated in serial sections with an AxioScop 2 Plus 
microscope (Zeiss). Lung pictures were acquired with a Zeiss Axio Imager Z2 
scanning microscope and metastases were quantified by Visiopharm 
application. 
 
Immunofluorescence staining 
For immunofluorescence analysis of frozen sections, organs were fixed at 4°C 
in 4% PFA for 2 hours, and cryopreserved for overnight in 20% sucrose in 
PBS prior to embedding in OCT freezing matrix. Cryosections were cut 7µm 
thick and dried for 30 min prior to rehydration in PBS. Slides were 
permeabilized with PBS/ 0.2% TritonX-100 and blocked for 30 min in PBS/5% 
normal goat serum and then incubated with the primary antibody in blocking 
buffer for 1 hour at room temperature. Immunofluorescence (IF) stainings 
were revealed by incubation with Alexa488 or Alexa568 labeled secondary 
antibodies (Invitrogen) and nuclei were stained with DAPI (Sigma-Aldrich). 
The stained slides were evaluated with a confocal laser scanning microscope 
(Leica SP5). Data were processed with Fiji Sofware. 
 
Statistical analysis 
Statistical analysis and graphs were generated using the GraphPad Prism 
software (GraphPad Software Inc, San Diego, CA). Statistical analyses were 
performed as indicated in the figure legends. 
 
Ethics statement 
Animal experiments were performed in strict accordance with the guidelines of 
the Swiss Federal Veterinary Office (SFVO) and the regulations of the 
Cantonal Veterinary Office of Basel-Stadt (license numbers 1878, 1907, and 
1908). During the whole course of animal experiments, all efforts were made 
to minimize animal suffering. 
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3.1.8 Supplemental data 
 
 
Supplemental Figure S1. Screening of epigenetic inhibitors for the reversion of 
M clone cells into an epithelial state (related to Figure 2) (A) Morphology of M2 
and M3 clone cells treated with 2µM 3-Deazaneplanocin A (DZNep), 2µM 5-Aza-2’-
deoxycytidine (DAC), and 100nM Trichostatin A (TSA), as evaluated by phase 
contrast microscopy. Scale bar, 100µm. (B) Immunoblotting analysis of the 
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expression of fibronectin (Fn1), N-cadherin (N-cad), and E-cadherin (E-cad) in M2 
and M3 clone cells in the absence or presence of 2µM DZNep, 2µM DAC, and 
100nM TSA for 72 hours. Immunoblotting for GAPDH was used as a loading. (C) 
Morphology of M3 clone cells and Py2T-LT cells treated with 2µM DAC, as visualized 
by phase contrast microscopy. Scale bar, 100µm. (D) Immunoblotting analysis of 
fibronectin (Fn1), N-cadherin (N-cad), E-cadherin (E-cad), and Vimentin (Vim) in M3 
clones and Py2T-LT cells treated or not with 2µM DAC for 6 days. Immunoblotting for 
GAPDH was used as a loading control. (E) The percentage of CpG methylation of 
the E-cadherin (E-cad) gene promoter was analyzed by bisulfite pyrosequencing in 
Py2T, Py2T-LT, Py2T-LT MET cells (reversible EMT) and in M1, M2, M3 clone cells 
(irreversible EMT). (F) Morphology of M3 clone cells and Py2T-LT cells treated with 
5µM CI994 and 5µM EPZ005687, as evaluated by phase contrast microscopy. Scale 
bar, 100µm. (G) Immunoblotting analysis of N-cadherin (N-cad), E-cadherin (E-cad), 
H3K27me3, and H3acetyl in M3 clone cells and in Py2T-LT cells treated or not with 
5µM CI994 and 5µM EPZ005687 for 6 days. Immunoblotting for GAPDH was used 
as a loading control for EMT markers. Immunoblotting for H3 was used as loading 
control for H3K27me3 and H3acetyl. 
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Supplemental Figure S2. HDAC inhibition causes a partial MET in M clone cells 
(related to Figure 3) (A) Immunoblotting analysis of H3 acetyl (H3ace), fibronectin 
(Fn1), N-cadherin (N-cad), E-cadherin (E-cad), and vimentin (Vim) in M1 and M2 
clone cells cultured  in the absence and presence of 2µM HDAC inhibitor (CI994) and 
10nM Panobinostat (LBH589) for 72 hours. Immunoblotting for H3 was used as 
loading control for H3 acetyl and GAPDH was used as a loading control for EMT 
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markers. (B) The morphology of M1 and M2 clone cells treated with 2µM CI994 and 
10nM LBH589 for 72 hours was evaluated by phase-contrast microscopy. Scale bar, 
100µm. (C) Quantitative RT-PCR analysis of the mRNA levels of E-cadherin (E-cad), 
Claudin4 (Cldn4), fibronectin (Fn1), vimentin (Vim), and Zeb1 in M1 and M2 clone 
cells treated with CI994 (2µM) and LBH589 (10nM) for 72 hours. Fold changes are 
related to mRNA levels in cells treated with DMSO diluent. (D) Confocal 
immunofluorescence microscopy analysis of the expression levels and localization of 
the epithelial marker E-cadherin (E-cad) and the mesenchymal marker vimentin 
(Vim) in M1 and M2 clone cells cultured in the absence and presence of 2µM CI994 
and 10nM LBH589 for 72 hours. Scale bar, 50µm. Data are displayed as mean ± 
SEM. Statistical values were calculated using a paired, two-tailed t-test. *, P < 0.05; 
**, P < 0.01. 
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Supplemental Figure S3. The Mbd3/NuRD complex is involved in the 
maintenance of a mesenchymal state (related to Figure 4) (A) Expression of 
fibronectin (Fn1), N-cadherin (N-cad), E-cadherin (E-cad), vimentin (Vim) and Mbd3 
in M3 clone cells and in Py2T-LT cells transfected with either siControl or siMbd3 
was evaluated by immunoblotting. Immunoblotting for GAPDH was used as a loading 
control. (B) Phase-contrast microscopy of M3 clone cells and Py2T-LT cells 
transfected with either siControl or siMbd3. Scale bar, 100µm. (C) Localization and 
expression levels of the epithelial markers E-cadherin (E-cad) and ZO-1 and the 
mesenchymal marker N-cadherin (N-cad) in M3 clone cells and in Py2T-LT cells 
transfected with either siControl or siMbd3 were analyzed by confocal 
immunofluorescence microscopy. Scale bar, 50µm. (D) RNA extracted from shMbd3 
or shControl-expressing cells and from M clone cells and Py2T-LT cells was 
extracted and sequenced by next generation sequencing. The Venn diagram 
represents the number of differentially regulated genes (n=1351; log2 fold change ≤-
0.58 and ≥+0.58; p-value≤0.05) that are shared in their differential expression 
between shMbd3 vs. shControl M3 clone cells and between M3 clone cells vs. Py2T-
LT cells. (E) The shared differently expressed genes (n=1351) identified in (D) were 
clustered in a heatmap. Columns and rows of the heatmap represent comparison 
and genes, respectively. Genes that are upregulated and downregulated are 
indicated by red and blue color code. 
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Supplemetal Figure S4. Loss of Tet2 induces a MET of M3 clone cells (related 
to Figure 5) (A) Tet2, fibronectin (Fn1), N-cadherin (N-cad), E-cadherin (E-cad), and 
Vimentin (Vim) protein expression levels in either siControl or siTet2-transfected M3 
clone cells and in Py2T-LT cells were evaluated by immunoblotting. Immunoblotting 
for GAPDH was used as a loading control. * represents a non-specific protein band 
bound by binding for anti-Tet2 antibodies. (B) Phase-contrast microscopy of M3 
clone cells and Py2T-LT cells transfected with either siControl or siTet2. Scale bar, 
100µm. (C) Localization and expression levels of the epithelial markers E-cadherin 
(E-cad) and ZO-1 and the mesenchymal marker N-cadherin (N-cad) in M3 clone cells 
and in Py2T-LT cells transfected with either siControl or siTet2 were analyzed by 
confocal immunofluorescence microscopy. Scale bar, 50µm. (D) RNA extracted from 
shMbd3 or shCopntrol-expressing cells and from Ms clone cells and from Py2T-LT 
cells was extracted and sequenced by next generation sequencing. The Venn 
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diagram represents the number of differentially regulated genes (n=1116; log2 fold 
change ≤-0.58 and ≥+0.58; p-value≤0.05) that are are shared in their differential 
expression between shTet2 vs. shControl M3 clone cells and between M3 clone cells 
vs. Py2T-LT cells. (E) The shared differently expressed genes (n=1116) identified in 
(D) were clustered in a heatmap. Columns and rows of the heatmap represent 
comparison and genes, respectively. Genes that are upregulated and downregulated 
are indicated by red and blue color code. 
 
 
 
Supplemental Figure S5. HDAC inhibition improved MET in Mbd3 and Tet2-
depleted M3 clone cells (related to Figure 6) (A) Quantitative RT-PCR analysis of 
the mRNA levels of Tet2 and Mbd3, as well as the epithelial genes E-cadherin (E-
cad) and Claudin4 (Cldn4) and the mesenchymal genes fibronectin (Fn1), vimentin 
(Vim), and Zeb1 in Tet2 and Mbd3-depleted M3 clone cells and in Py2T-LT cells 
cultured for 72 hours in the absence and presence of 2µM HDAC inhibitor CI994. 
Fold changes are related to the cells stably expressing shControl in the absence of 
CI994. (B) Confocal immunofluorescence microscopy analysis of the localization and 
expression levels of the epithelial marker protein E-cadherin (E-cad) n M3 clone cells 
and Py2T-LT cells expressing either shControl, shTet2, or shMbd3 and cultured for 
72 hours in the absence and presence of 2µM CI994. Scale bar, 50µm. Data are 
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displayed as mean ± SEM. Statistical values were calculated using a paired, two-
tailed t-test. *, P < 0.05; **, P < 0.01, ***; P < 0.001; ****, P < 0.0001. 
 
	
 
Supplemental Figure S6 (related to Figure 6) (A) The left Venn diagram 
represents the number of differentially regulated genes shared between the following 
three comparisons: shMbd3 vs. shControl, shTet2 vs. shControl and M3 clone cells 
control vs. M3 clone cells treated with CI994 for 72hr. The right Venn diagram 
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represents the number of differentially regulated genes shared between the 
comparisons: shMbd3 vs. shMbd3 + CI994 and shTet2 vs. shTet2 + CI994. The 
middle Venn diagram represents the number of differentially regulated genes that are 
common between the shared signatures of the left and the right Venn diagram. 
These common 92 genes are referred to as induced MET (iMET) genes. (B) 
Heatmap of the expression of the 92 shared differentially expressed iMET genes 
identified in (A) in the shRNA-manipulated and HDAC inhibitor treated M3 clone cells 
and during a time course of MET in Py2T-LT cells induced by the withdrawal of 
TGFβ. Columns and rows of the heatmap represent comparison and genes, 
respectively. Genes that are upregulated and downregulated are indicated by red 
and blue color code. MET: TGFβ was removed at different time points. These 
different time points were divided into three subcategories. Early MET (12h, 24h, 
48h), Middle MET (3d, 4d, 5d, 7d, and 10d), Late MET (15d, 22d, 29d). Red arrows 
represent upregulated genes. Blue arrows represent downregulated genes. Green 
lines represent non-regulated genes. 
 
Supplementary Table S1. List of the 92 genes that are shared in their 
differential expression between M3 clone cells either depleted of Mbd3 or 
depleted of Tet2 or inhibited in their HDAC activity. Numbers represent fold 
changes in expression. 
Symbol induced MET reversible MET 
 M3.CI994 
vs 
M3 
Tet2 
vs 
Ctrl 
Mbd3 
vs 
Ctrl 
shTet2.CI994 
vs 
Tet2 
Mbd3.CI994 
vs 
Mbd3 
Early Middle Late 
C3 2.87 0.99 -2.88 2.44 2.30 0.87 4.64 8.85 
Myh14 1.11 3.27 2.73 1.49 1.08 1.34 4.96 8.36 
Bst1 3.14 2.24 1.26 1.75 1.75 -0.05 3.13 7.03 
Gda 2.01 -1.94 -5.32 2.36 2.77 1.33 5.00 6.97 
Ocln 3.62 2.31 2.50 1.10 1.40 0.05 2.32 6.69 
Sorbs2 1.61 1.98 3.52 1.78 0.79 0.88 2.12 5.68 
Ly6a 1.99 0.69 1.32 1.97 0.81 1.23 4.86 5.24 
Erbb3 2.41 2.19 1.91 0.71 1.05 -0.10 1.86 4.91 
C1s1 2.70 -2.15 -3.52 4.21 3.16 -0.61 3.09 4.78 
Grb7 4.29 3.08 3.43 1.01 1.08 -0.27 1.30 4.45 
Tnfrsf9 0.88 -2.18 -1.79 1.87 2.11 0.16 2.00 3.52 
Mgst1 1.29 -1.86 -1.39 1.09 0.63 -0.41 2.01 3.30 
Cxcl16 2.36 2.21 3.19 0.77 0.86 -0.18 0.28 3.16 
Prl2c3 -1.75 -3.17 -2.18 0.69 0.82 1.63 1.58 3.05 
Prl2c4 -1.75 -3.18 -2.18 0.69 0.82 1.62 1.58 3.05 
Prickle2 1.79 -1.89 -5.89 2.03 2.73 -0.47 1.97 2.83 
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Ccl2 1.81 -3.28 -2.57 3.17 3.59 0.58 1.12 2.57 
Pmp22 0.71 -0.76 -0.63 1.09 1.64 0.66 2.44 2.22 
Map2 1.32 -0.74 -1.21 0.59 0.82 0.74 2.70 2.18 
Mcpt8 2.92 1.67 1.50 0.93 0.94 0.53 -0.10 2.12 
Mapk13 2.44 3.02 2.09 0.91 1.02 -0.42 0.27 2.00 
Gstt3 1.49 1.10 1.19 1.10 1.26 0.13 1.45 2.00 
Slco4a1 2.03 -3.15 1.46 2.42 1.57 0.61 0.81 1.86 
Arrdc4 2.09 -1.47 -2.04 1.45 1.72 -0.12 0.18 1.70 
Pdk1 0.66 0.77 -0.86 -1.52 -1.13 0.16 1.89 1.66 
Rom1 2.08 2.81 2.03 2.10 2.71 0.16 0.94 1.64 
Cldn3 0.72 2.25 2.36 1.55 1.09 -0.66 -0.55 1.60 
Cdc42bpg 0.69 1.66 0.79 1.09 0.80 -0.35 0.43 1.57 
Bdkrb2 0.80 1.83 2.04 1.17 0.86 0.17 0.20 1.55 
Sord 1.80 -0.80 -1.77 1.24 1.56 -0.23 1.83 1.43 
Atp9a 0.66 0.62 1.45 1.52 0.83 -0.41 0.51 1.42 
H2-T23 1.27 1.29 1.35 1.56 1.42 -0.26 1.52 1.41 
Tgm2 1.48 0.83 -0.94 0.77 1.04 -0.69 2.06 1.38 
Cldn4 2.70 2.87 3.50 1.14 0.92 -1.34 -2.00 1.34 
H2-D1 1.97 1.25 1.40 1.95 1.48 -0.27 -0.12 1.33 
Osgin1 1.61 2.11 1.98 1.15 0.67 -0.24 0.58 1.33 
H2-L 1.85 1.42 1.62 2.34 1.81 -0.29 -0.14 1.28 
MARCH9 1.18 0.87 1.16 1.33 1.29 -0.52 -0.02 1.18 
Rnd1 0.67 1.98 1.30 1.37 1.04 0.51 -0.24 1.03 
Amigo2 -1.27 -1.13 -1.41 -1.58 -1.42 1.21 2.58 1.01 
Jund 0.72 0.70 0.82 0.93 0.71 0.00 0.29 0.93 
Capn5 1.68 0.87 0.85 1.03 0.95 -0.12 1.08 0.81 
Rem2 0.71 1.10 1.45 1.42 1.14 -0.36 -1.04 0.77 
Cystm1 0.77 1.24 1.08 1.06 0.73 -0.37 0.09 0.76 
Epha1 1.37 3.56 3.00 2.30 1.92 1.19 -0.16 0.74 
Igf2bp1 2.90 2.01 2.01 1.19 1.88 0.15 -0.03 0.69 
Itgb7 -1.01 -1.77 -1.80 -2.62 -1.96 0.50 1.24 0.66 
Pvrl2 1.19 1.23 2.27 1.66 1.39 -0.19 -0.34 0.62 
Gsn 1.09 1.35 1.06 0.92 1.06 -0.25 0.14 0.54 
Slc5a3 -0.93 -0.69 -1.59 -2.28 -1.28 0.73 1.69 0.52 
H2-K1 1.51 0.76 1.09 1.72 1.26 -0.30 -0.36 0.42 
Atp5d 0.62 0.97 1.10 1.16 1.00 0.16 0.14 0.35 
Zbtb7b 0.76 0.73 0.96 0.84 0.80 -0.04 0.31 0.32 
4933433H22
Rik 1.25 1.61 1.50 1.49 1.33 0.21 0.35 0.20 
Rnase4 1.22 -2.10 -1.24 2.48 1.36 -0.36 0.76 0.16 
Por 0.76 1.04 0.76 0.65 0.61 -0.10 0.18 0.15 
BC029722 0.71 1.30 0.60 0.95 0.70 0.25 0.92 0.15 
Mr1 1.21 -1.09 -1.47 0.98 1.32 -0.62 0.61 0.04 
Abtb2 -0.63 1.14 1.46 0.97 0.88 -0.38 -0.95 0.00 
Mall 1.69 2.13 1.89 0.77 0.92 0.06 0.03 0.00 
Renbp 0.75 -0.73 -1.75 0.80 1.56 0.06 0.43 -0.01 
Gm6644 0.67 0.83 0.95 0.67 0.74 0.74 0.60 -0.05 
Akr1b3 0.67 0.83 0.95 0.67 0.74 0.73 0.59 -0.06 
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Nptx1 -1.52 -1.93 -0.99 -1.63 -1.36 -1.10 -0.70 -0.07 
Stom 0.87 0.87 1.28 0.98 0.68 -0.71 -0.39 -0.29 
Aacs 0.85 0.73 1.04 0.86 0.61 -0.17 -0.51 -0.30 
Rras 1.08 0.95 1.28 0.75 0.94 -0.27 -0.58 -0.36 
Prkcd 1.13 1.00 1.17 0.88 1.15 -0.26 -1.05 -0.39 
Tmem40 2.99 2.94 2.54 0.73 0.70 -0.26 -2.35 -0.42 
Prrx1 -1.02 -3.33 -1.79 -1.20 -1.11 0.02 0.84 -0.52 
Procr 1.14 2.46 1.20 0.91 1.02 -0.38 -0.47 -0.60 
Ddx26b -0.73 -0.69 -0.71 -0.98 -0.99 0.15 0.49 -0.65 
N4bp2 -1.30 -0.83 -0.61 -1.00 -1.05 0.04 -0.27 -0.71 
Sema5a -1.42 -1.25 -1.24 -2.74 -1.56 -0.42 1.61 -0.71 
Tubb2b 1.01 0.97 0.98 1.64 1.30 -0.30 -1.16 -0.74 
Fbln2 0.92 1.10 1.79 1.63 1.25 -0.07 -1.17 -0.81 
Ank -0.99 -2.37 -0.98 -1.55 -0.81 0.26 1.03 -0.81 
Pxdc1 1.05 0.68 0.62 0.67 0.71 -0.45 -1.73 -0.94 
Cc2d2a -0.82 -0.87 -0.79 -1.42 -1.36 0.11 0.46 -0.96 
Rcbtb2 -1.32 -1.04 -1.03 -1.28 -2.05 0.21 0.28 -0.96 
Rhob 1.21 1.01 1.13 0.69 0.75 -0.03 -0.72 -0.97 
Frmd4a -0.96 -0.61 -0.71 -1.51 -0.97 -0.09 -0.15 -0.98 
Rdh10 -1.23 -0.92 -0.80 -1.13 -1.31 -0.27 -0.24 -1.04 
Fgd3 1.06 1.13 1.45 0.94 1.05 -0.75 -2.37 -1.27 
Dscc1 -1.05 -0.91 -1.01 -1.10 -1.08 0.44 -0.01 -1.31 
Adam12 -1.58 1.80 1.35 -1.08 -0.93 -0.38 -3.91 -1.41 
Lrp11 1.56 -0.79 1.03 2.37 1.37 0.07 -0.63 -1.62 
Ctgf 1.44 1.59 1.70 1.71 0.84 -0.54 -0.83 -1.75 
Tnnt2 0.92 0.69 0.82 0.61 0.64 -0.40 -2.28 -2.44 
Ret 0.67 2.83 4.86 1.42 1.31 0.22 -1.71 -4.02 
Mmp13 4.08 0.84 -1.49 1.65 3.07 -2.58 -4.54 -5.35 
Serpine1 1.60 2.24 2.74 1.15 1.20 -0.97 -5.20 -5.82 
 
Supplemental Table S2. Primers for quantitative RT-PCR 
Primer name Sequences (5’-3’) 
Rpl19 Forward primer CTCGTTGCCGGAAAAACA 
Rpl19 Reverse primer TCATCCAGGTCACCTTCTCA 
E-cadherin Forward primer CGACCCTGCCTCTGAATCC 
E-cadherin Reverse primer TACACGCTGGGAAACATGAGC 
Claudin4 Forward primer GTCCTGGGAATCTCCTTGGC 
Claudin4 Reverse primer TCTGTGCCGTGACGATGTTG 
Fibronectin Forward primer CCCAGACTTATGGTGGCAATT 
Fibronectin Reverse primer AATTTCCGCCTCGAGTCTGA 
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Vimentin Forward primer CCAACCTTTTCTTCCCTGAA 
Vimentin Reverse primer TTGAGTGGGTGTCAACCAGA 
Snail Forward primer CTCTGAAGATGCACATCCGAA 
Snail Reverse primer GGCTTCTCACCAGTGTGGGT 
Zeb1 Forward primer GCCAGCAGTCATGATGAAAA 
Zeb1 Reverse primer TATCACAATACGGGCAGGTG 
Twist1 Forward primer GCCGGAGACCTAGATGTCATTG 
Twist1 Reverse primer CACGCCCTGATTCTTGTGAA 
Tet2 Forward primer AGAGAAGACAATCGAGAAGTCGG 
Tet2 Reverse primer CCTTCCGTACTCCCAAACTCAT 
Mbd3 Forward primer GAAGCTAAGTGGATTGAGTGCC 
Mbd3 Reverse primer GACAGCAGCGTCTCATCTGTA 
 
Supplemental Table S3. Primers for PCR and Pyrosequencing 
Gene name Sequences (5’-3’) 
E-cadherin  F: GTTTTTTGGTTGTTATTTGTAGGTG 
R: CTCTATCTCAAACAAAAACCCTACTC 
Seq1: GGTTGTTATTTGTAGGTG 
Seq2: AGAATTTTTGTTAGATTTT 
Seq3: GTGGAGGGTTTTGAT 
Seq4: TTTTTTAAGAAAGTTGGGATT 
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4 Conclusion and future plans 	
Epithelial-mesenchymal transition (EMT) represents cellular plasticity, 
which involves dynamic switches from epithelial to mesenchymal cell states. 
EMT is a process that endows stationary epithelial tumor cells with increased 
motility and invasiveness. The reverse process MET is required for the 
metastatic outgrowth in distant tissues. Hence, elucidating the regulatory 
mechanisms during epithelial-mesenchymal plasticity provides important 
insights to prevent metastasis.  
In this study, we used a different approach to study the epithelial 
mesenchymal plasticity by comparing irreversible and reversible EMT model 
systems. During characterization of these two EMT systems, we noticed that 
irreversible and reversible EMT cells exhibit in vitro and in vivo differences. 
We observed different expression levels of EMT markers as well as 
differences in the whole transcriptome identified by RNA-sequencing. We 
determined 6624 differentially regulated genes in the irreversible EMT cells 
compared to the reversible EMT cells. Further, in vivo analysis indicated that 
the irreversible mesenchymal cells exhibit higher tumor initiation, tumor 
formation and ability to home in to the lungs than the reversible EMT cells. It 
is important to note that even though we observed mesenchymal primary 
tumors, we do not have evidence whether they retain their mesenchymal state 
in the metastatic site. These results may indicate the existence of the different 
mesenchymal cell types and states, with different EMT signatures and 
functional properties.   
We provided evidence for the differences in epigenetic modifiers 
between the irreversible and reversible EMT cells. We showed that the 
Mbd3/NuRD complex involving histone deacetylases (HDACs) and Tet2 
hydroxylase act in the maintenance of the mesenchymal state in the 
irreversible EMT cells. Additionally, we deduced a list of genes that are 
regulated by Mbd3, Tet2 in the absence and presence of HDACs in the 
irreversible EMT cells. We further reported the depletion of Mbd3, Tet2 in the 
absence and presence of HDAC inhibitor led to a mesenchymal-epithelial 
transition (MET), as well as diminishing the tumor growth and metastasis. 
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Deeper mechanistic details of the working principles and the regulatory 
networks of these molecules during the cell state transitions of EMT are 
required to be explained. This will give us a broad perspective to understand 
the genome-wide regulation of the cell plasticity by epigenetic regulators 
during malignant tumor progression and metastasis. Further studies could 
help to identify specific inhibitors for the TET enzymes and the combination 
treatments with HDAC inhibitors could open a new avenue for more effective 
therapy. Instead of the targeting single gene mutations, epigenetic modifiers 
are more attractive therapeutic targets due to their wide spread acting 
mechanisms and reversible nature.  
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